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1. General Introduction 
1.1 The role of atherosclerosis in stroke 
Cardiovascular diseases (CVD) are the main causes of morbidity and mortality 
worldwide (1, 2). Of all CVD deaths, stroke is the second leading cause after 
myocardial infarction (3, 4). Approximately 87% of strokes are of ischemic origin, 
and the remaining 13% are comprised of intracerebral or subarachnoid 
hemorrhages (5).  
An ischemic stroke is defined as a syndrome of sudden, focal or global 
neurological deficit that lasts longer than 24 hours. Although ischemic strokes can 
be caused by cardiac thrombo-emboli, vasculitis or dissection, the atherosclerotic 
disease is the most common cause of ischemic stroke. Especially, when located in 
the carotid arteries, atherosclerosis is thought to contribute to at least 20-25% of 
all ischemic strokes (4, 6). 
Atherosclerosis is characterized by thickening of the arterial wall due to the 
accumulation of lipids, calcium, and fibrous material (atherosclerotic plaques) 
under the influence of risk factors (e.g. smoking, obesity) (7). 
An important location in the trajectory of the carotid artery that is commonly 
affected by atherosclerosis is the bifurcation (i.e. the point at which the common 
carotid artery splits into the external and internal carotid artery). Atherosclerotic 
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plaque formation at this location is an important source for the formation of 
thrombus and or subsequent embolization that may lead to ischemic stroke (8). 
(9, 10). Over the years, specific characteristics of the atherosclerotic plaque have 
been identified to predispose for abovementioned formation of thrombus or 
emboli. These include the plaque size, but more importantly the presence of 
certain components in the plaque, such as intraplaque hemorrhage, lipid core, or 
calcification. Imaging techniques are essential to visualize and quantify these 
specific characteristics of the plaque and may aid in determining the progression 
of atherosclerosis.  
Hence, the general aim of this thesis is to contribute to our understanding of the 
etiology and pathophysiology of carotid atherosclerosis by means of in-vivo, 
state-of-the-art imaging of atherosclerosis in a sample of community-dwelling 
middle-aged and elderly people. 
1.2 Magnetic Resonance Imaging of carotid atherosclerosis 
Current guidelines for the prevention of the strokes in patients with carotid 
atherosclerosis are based on the assessment of the carotid degree of luminal 
stenosis (11, 12) according to North American Symptomatic Carotid 
Endarterectomy Trial (NASCET) and European Carotid Surgery Trial  (ECST) criteria, 
and is used as a parameter for stratification of severity of atherosclerosis in clinical 
decision making.  
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Over the last decades, advanced non-invasive visualization of carotid artery 
atherosclerosis using medical imaging has been hugely improved. Given the 
topography and relative superficial localization of the carotid artery in the neck,  
various non-invasive imaging modalities, including ultrasound, computed 
tomography an magnetic resonance, have been optimized to visualize 
atherosclerotic disease (13). Especially, magnetic resonance imaging (MRI) 
techniques have enabled feasible non-invasive characterization of 
atherosclerosis, including quantification of carotid stenosis and advanced plaque 
imaging, (determination of intraplaque hemorrhage, lipid core, and calcification). 
MRI accuracy has been validated against a histological background with high 
reproducibility (14). (15). Several MRI-based prospective studies found that non-
calcified components of the plaque, such as lipid necrotic core or intraplaque 
hemorrhage, correlate strongly with the occurrence of cerebrovascular events (6, 
16, 17).  
1.3 The role of hormones and cardiovascular medication in carotid 
atherosclerosis  
Various risk factors have been found to influence the initiation of the 
atherosclerotic process in the carotid artery, led by atherogenic lipoproteins and 
inflammatory pathophysiological mechanisms. Additional risk factors including 
hypertension, diabetes mellitus, and smoking, contribute to the development and 
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further progression of the plaque size and volume, thereby increasing the risk of 
plaque rupture and consequently ischemic stroke (18). Interestingly, lipid 
metabolism (lipoproteins) is strongly influenced by circulating hormones, such as 
insulin and sex hormones (19, 20), and circulating hormones have been linked 
with risk of cardiovascular disease (21, 22). Whether hormones are directly 
implicated in development or progression of the atherosclerotic plaque remains 
unknown, but would provide important information on the risk prediction of 
cardiovascular disease (21, 22).    
To prevent cardiovascular events different treatment options are available, 
including drug therapy. Initially, at early stages of the disease a lifestyle 
modification, diet change, smoking cessation, and more physical activity are 
recommended (23). In more advanced stages medication treatment is provided. 
At this stage, drug treatment is initiated to prevent hard endpoints, such as stroke, 
but whether such treatment directly influences the underlying atherosclerotic 
disease remains unknown. Current guidelines for the management of patients 
having one or more cardiovascular risk factors recommend the prescription of 
antihypertensive medication, lipid-lowering medication, and antithrombotic 
medication (24). Although, these medical treatments have established their 
beneficial effect on preventing CVD events and lower the overall cardiovascular 
risk, their effect on existing carotid atherosclerotic plaque remains unknown. 
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Beyond that, although the drug treatment provides beneficial effects, 
understanding the mechanisms on how they interplay with atherosclerotic plaque 
characteristics and constituent components, may provide extensive 
understanding on pathophysiology of these processes. Whether medical 
treatment trigger molecular transitions into the carotid plaque and this way 
plaque modifications remains unknown. Understanding such pathways may 
further help to improve medical treatment strategies which would later be 
translated to reduce the CVD event rates and would be an important element to 
improve the prevention of ischemic events.  
1.4 Outline of this thesis 
In Chapter 2, the capacity of magnetic resonance imaging (MRI) to quantify 
carotid artery calcification is assessed and compared to the golden standard for 
calcification assessment, i.e. computed tomography.  
Circulating hormones play an important role in cardiometabolic health and are 
strongly linked to cardiovascular disease (21, 25, 26). The third chapter focuses on 
the impact of circulating hormones on carotid plaque composition. Chapter 3.1 
demonstrates the role of the serum insulin and glucose on carotid plaque 
composition, whereas Chapter 3.2 highlights the role of endogenous estradiol 
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and testosterone levels in carotid plaque composition and the risk of stroke in 
subjects with carotid atherosclerosis.  
The fourth chapter is focused on the role of medical treatment used for 
prevention of cardiovascular events. The goal of Chapter 4.1 was to elucidate 
associations of lipid-lowering medication (statins) with composition of the 
plaque. Chapter 4.2 assessed the effect of antithrombotic treatment on carotid 
plaque composition.   
Finally, in Chapter 5, the main findings of the studies included in this thesis are 
summarized and put into clinical context. Finally, directions for future research 
are given.      
 
CHAPTER 1 
19 
REFERENCES: 
1. Thrift AG, Cadilhac DA, Thayabaranathan T, Howard G, Howard VJ, 
Rothwell PM, Donnan GA. Global Stroke Statistics. International Journal 
of Stroke. 2014;9(1):6-18. 
2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das 
SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi 
CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, 
Mackey RH, Magid DJ, McGuire DK, Mohler ER, 3rd, Moy CS, Muntner P, 
Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, 
Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, 
Turan TN, Virani SS, Woo D, Yeh RW, Turner MB, American Heart 
Association Statistics C, Stroke Statistics S. Executive Summary: Heart 
Disease and Stroke Statistics-2016 Update: A Report From the American 
Heart Association. Circulation. 2016;133(4):447-54. 
3. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons From 
Sudden Coronary Death. Arteriosclerosis, Thrombosis, and Vascular 
Biology. 2000;20(5):1262-75. 
4. Ooi YC, Gonzalez NR. Management of extracranial carotid artery disease. 
Cardiol Clin. 2015;33(1):1-35. 
CHAPTER 1 
20 
5. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, 
Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs 
J, Moy C, Nichol G, O’Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, 
Wilson M, Hong Y. Heart Disease and Stroke Statistics&#x2014;2008 
Update. Circulation. 2008;117(4):e25-e146. 
6. Saba L, Saam T, Jäger HR, Yuan C, Hatsukami TS, Saloner D, Wasserman 
BA, Bonati LH, Wintermark M. Imaging biomarkers of vulnerable carotid 
plaques for stroke risk prediction and their potential clinical implications. 
The Lancet Neurology. 2019. 
7. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, 
Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White 
R, Zhang Z, Serruys PW. A Prospective Natural-History Study of Coronary 
Atherosclerosis. New England Journal of Medicine. 2011;364(3):226-35. 
8. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating 
the biology of atherosclerosis. Nature. 2011;473(7347):317-25. 
9. Auscher S, Heinsen L, Nieman K, Vinther KH, Logstrup B, Moller JE, 
Broersen A, Kitslaar P, Lambrechtsen J, Egstrup K. Effects of intensive 
lipid-lowering therapy on coronary plaques composition in patients with 
acute myocardial infarction: Assessment with serial coronary CT 
angiography. Atherosclerosis. 2015;241(2):579-87. 
CHAPTER 1 
21 
10. Bos D, Leening MJ, Kavousi M, Hofman A, Franco OH, van der Lugt A, 
Vernooij MW, Ikram MA. Comparison of Atherosclerotic Calcification in 
Major Vessel Beds on the Risk of All-Cause and Cause-Specific Mortality: 
The Rotterdam Study. Circ Cardiovasc Imaging. 2015;8(12). 
11. Naylor AR, Ricco JB, de Borst GJ, Debus S, de Haro J, Halliday A, Hamilton 
G, Kakisis J, Kakkos S, Lepidi S, Markus HS, McCabe DJ, Roy J, Sillesen H, 
van den Berg JC, Vermassen F, Esvs Guidelines C, Kolh P, Chakfe N, 
Hinchliffe RJ, Koncar I, Lindholt JS, Vega de Ceniga M, Verzini F, Esvs 
Guideline R, Archie J, Bellmunt S, Chaudhuri A, Koelemay M, Lindahl AK, 
Padberg F, Venermo M. Editor's Choice - Management of Atherosclerotic 
Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of 
the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc 
Surg. 2018;55(1):3-81. 
12. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz 
MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner 
SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA. 
Guidelines for the prevention of stroke in patients with stroke and 
transient ischemic attack: a guideline for healthcare professionals from 
the American Heart Association/American Stroke Association. Stroke. 
2014;45(7):2160-236. 
CHAPTER 1 
22 
13. Owen DR, Lindsay AC, Choudhury RP, Fayad ZA. Imaging of 
atherosclerosis. Annual review of medicine. 2011;62:25-40. 
14. Wang J, Balu N, Canton G, Yuan C. Imaging biomarkers of cardiovascular 
disease. Journal of magnetic resonance imaging: JMRI. 2010;32(3):502-
15. 
15. Saam T, Ferguson MS, Yarnykh VL, Takaya N, Xu D, Polissar NL, Hatsukami 
TS, Yuan C. Quantitative evaluation of carotid plaque composition by in 
vivo MRI. Arterioscler Thromb Vasc Biol. 2005;25(1):234-9. 
16. Takaya N, Yuan C, Chu B, Saam T, Underhill H, Cai J, Tran N, Polissar NL, 
Isaac C, Ferguson MS, Garden GA, Cramer SC, Maravilla KR, Hashimoto B, 
Hatsukami TS. Association between carotid plaque characteristics and 
subsequent ischemic cerebrovascular events: a prospective assessment 
with MRI--initial results. Stroke. 2006;37(3):818-23. 
17. Esposito-Bauer L, Saam T, Ghodrati I, Pelisek J, Heider P, Bauer M, Wolf P, 
Bockelbrink A, Feurer R, Sepp D, Winkler C, Zepper P, Boeckh-Behrens T, 
Riemenschneider M, Hemmer B, Poppert H. MRI Plaque Imaging Detects 
Carotid Plaques with a High Risk for Future Cerebrovascular Events in 
Asymptomatic Patients. PLOS ONE. 2013;8(7):e67927. 
18. Selwaness M, Hameeteman R, Van 't Klooster R, Van den Bouwhuijsen Q, 
Hofman A, Franco OH, Niessen WJ, Klein S, Vernooij MW, Van der Lugt A, 
CHAPTER 1 
23 
Wentzel JJ. Determinants of carotid atherosclerotic plaque burden in a 
stroke-free population. Atherosclerosis. 2016;255:186-92. 
19. Gil-Campos M, Cañete R, Gil A. Hormones regulating lipid metabolism 
and plasma lipids in childhood obesity. International Journal of Obesity. 
2004;28(3): S75-S80. 
20. Palmisano BT, Zhu L, Stafford JM. Role of Estrogens in the Regulation of 
Liver Lipid Metabolism. Adv Exp Med Biol. 2017;1043:227-56. 
21. Després J-P, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, 
Lupien P-J. Hyperinsulinemia as an Independent Risk Factor for Ischemic 
Heart Disease. New England Journal of Medicine. 1996;334(15):952-8. 
22. Scarabin-Carre V, Canonico M, Brailly-Tabard S, Trabado S, Ducimetiere 
P, Giroud M, Ryan J, Helmer C, Plu-Bureau G, Guiochon-Mantel A, 
Scarabin PY. High level of plasma estradiol as a new predictor of ischemic 
arterial disease in older postmenopausal women: the three-city cohort 
study. Journal of the American Heart Association. 2012;1(3):e001388. 
23. Franco OH, de Laet C, Peeters A, Jonker J, Mackenbach J, Nusselder W. 
Effects of Physical Activity on Life Expectancy With Cardiovascular 
Disease. Archives of Internal Medicine. 2005;165(20):2355-60. 
24. Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, 
Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, 
CHAPTER 1 
24 
Kownator S, Mazzolai L, Naylor AR, Roffi M, Rother J, Sprynger M, Tendera 
M, Tepe G, Venermo M, Vlachopoulos C, Desormais I. 2017 ESC 
Guidelines on the Diagnosis and Treatment of Peripheral Arterial 
Diseases, in collaboration with the European Society for Vascular Surgery 
(ESVS): Document covering atherosclerotic disease of extracranial carotid 
and vertebral, mesenteric, renal, upper and lower extremity 
arteriesEndorsed by: the European Stroke Organization (ESO)The Task 
Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of 
the European Society of Cardiology (ESC) and of the European Society for 
Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. 
25. Bano A, Chaker L, Mattace-Raso FUS, Lugt Avd, Ikram MA, Franco OH, 
Peeters RP, Kavousi M. Thyroid Function and the Risk of Atherosclerotic 
Cardiovascular Morbidity and Mortality. Circulation Research. 
2017;121(12):1392-400. 
26. Scarabin‐Carré V, Canonico M, Brailly‐Tabard S, Trabado S, Ducimetière 
P, Giroud M, Ryan J, Helmer C, Plu‐Bureau G, Guiochon‐Mantel A, 
Scarabin PY. High Level of Plasma Estradiol as a New Predictor of Ischemic 
Arterial Disease in Older Postmenopausal Women: The Three City-Cohort 
Study. Journal of the American Heart Association. 2012;1(3):e001388. 
 
CHAPTER 2 
25 
Chapter 2  
Comparison of CT and MRI detection and 
quantification of carotid artery 
calcification 
CHAPTER 2 
26 
CHAPTER 2 
27 
Chapter 2  
Comparison of CT and MRI for the 
detection and quantification of carotid 
artery calcification and their comparative 
association with the history of stroke 
 
 
 
 
 
 
 
Blerim Mujaj1, Andrés M. Arias Lorza2, Arna van Engelen2, Marleen de Bruijne2,4, Oscar 
H. Franco1, Aad van der Lugt3, Meike W. Vernooij1,3, Daniel Bos1,3,5 
1 Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the 
Netherlands 
2 Biomedical Imaging Group Rotterdam, Departments of Medical Informatics, Radiology, and 
Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, the Netherlands 
3 Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center, 
Rotterdam, the Netherlands 
4 Department of Computer Science, University of Copenhagen, Denmark 
5 Department of Clinical Epidemiology, Harvard TH Chan School of Public Health, Boston, 
United States of America 
 
Journal of cardiovascular magnetic resonance. 2017;19(1):28. 
CHAPTER 2 
28 
Abstract  
Background 
Carotid artery atherosclerosis is an important risk factor for stroke. As such, 
quantitative imaging of carotid artery calcification, as a proxy of atherosclerosis, has 
become a cornerstone of current stroke research. Yet, population-based data 
comparing the main imaging modalities (computed tomography and magnetic 
resonance imaging) for the detection and quantification of calcification remain 
scarce. 
Methods 
A total of 684 participants from the population-based Rotterdam Study underwent 
both a CT-examination and an MRI-examination of the carotid artery bifurcation to 
quantify the amount of carotid artery calcification (mean interscan interval: 4.9 ± 1.2 
years). We investigated the correlation between the amount of calcification 
measured on CT and an MRI using Spearman’s correlation coefficient, Bland-Altman 
plots, and linear regression. In addition, using logistic regression modeling, we 
assessed the association of CT- and MRI-based calcification volumes with a history 
of stroke. 
Results 
We found a strong correlation between CT- and MRI-based calcification volumes 
(Spearman’s correlation coefficient:0.86, p-value ≤0.01). Bland-Altman analyses 
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showed a good agreement, though CT-based calcification volumes were 
systematically larger. Finally, calcification volume assessed with either imaging 
modality was associated with a history of stroke with similar effect estimates (odds 
ratio (OR) per 1-SD increase in calcification volume: 1.52 (95%CI:1.00;2.30) for CT, 
and 1.47 (95%CI:1.01;2.14) for MRI. 
Conclusion 
CT-based and MRI-based volumes of carotid artery calcification are highly correlated, 
but MRI-based calcification is systematically smaller than those obtained with CT. 
Despite this difference, both provide comparable information with regard to a history 
of stroke. 
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BACKGROUND 
Atherosclerosis located at the bifurcation of the carotid artery is an important risk 
factor for stroke (1-5). As such, quantification of the severity of carotid 
atherosclerosis has become an increasingly important topic in stroke research. 
Multiple non-invasive imaging techniques, including ultrasound, computed 
tomography (CT), and magnetic resonance imaging (MRI), are currently available to 
obtain measures of the extent of atherosclerosis (6). An important advantage of CT 
and MRI is that both modalities offer possibilities for detailed characterization and 
quantification of the atherosclerotic plaque (7). The mostly studied characteristic of 
the atherosclerotic plaque is calcification, given that it is one of the most prominent 
plaque characteristics and represents a reliable marker of the underlying plaque 
burden (8). For the visualization of calcification, non-contrast CT is acknowledged to 
be superior to any other imaging modality (9). Yet, thanks to rapid technological 
advances, non-contrast MRI now also allows for the detection and quantification of 
calcification in the atherosclerotic plaque (10) and has the major advantage over CT 
that it does not involve radiation exposure. Moreover, with MRI it is possible to 
visualize additional plaque characteristics such as intraplaque hemorrhage or lipid-
rich necrotic core which provide unique additional information on the disease. 
Despite these potential advantages of MRI, it remains unclear whether calcification 
volumes obtained with MRI are comparable to those measured with CT. Against this 
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background, we set out to quantify and compare CT-based and MRI-based carotid 
artery calcification in terms of absolute volumes and with respect to the history of 
stroke as a relevant clinical outcome, in participants from the population-based 
Rotterdam Study. 
MATERIAL AND METHODS 
Setting 
This study was carried out within the framework of the Rotterdam Study, a 
prospective population-based study among middle-aged and elderly persons (11). 
Between 2003 and 2006, all participants that visited the research center were invited 
to undergo multi-detector computed tomography (MDCT) to quantify vascular 
calcification in multiple vessels, including the carotid artery bifurcation (12). In total 
2,524 participants were scanned.  
From October 2007 onwards, carotid MRI was incorporated in the Rotterdam Study. 
Between 2007 and 2012, we invited 2,666 participants to undergo an MRI 
examination of the carotid arteries to study atherosclerotic disease. These 
participants were selected on the basis of the presence of atherosclerosis in at least 
one carotid artery on ultrasound examination (defined as intima-media thickness 
>2.0 mm in one or both carotid arteries), which is regularly performed in all 
Rotterdam Study participants. In total 1,982 participants underwent carotid MRI. 
From these 1,982, 808 participants had also undergone a CT-examination. Due to 
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image artifacts or low image quality (n=31, or errors in the MRI registration process 
needed for analysis (n=93) 124 participants were excluded, leaving 684 participants 
with usable CT and MRI data for the current study. The mean time interval between 
CT scan and MRI scan was 4.9 years (standard deviation 1.2 years). 
Assessment of CT-based calcification 
We performed a non-enhanced CT-examination (16-or 64-slice MDCT Somatom 
Sensation, Siemens, Forchheim, Germany) that reached from the aortic arch to the 
intracranial vasculature, to visualize calcification in the extracranial carotid arteries. 
The detailed information regarding the scan protocol is described elsewhere (12). In 
short, the following scan parameters were used: 16 x 0.75 mm collimation, 120 kVp, 
100 effective mAs, and 0.5 s rotation time, with a normalized pitch of 1. Images were 
reconstructed with an effective slice width of 1 mm, a reconstruction interval of 0.5 
mm, and a medium sharp convolution kernel (12). Calcification in the extra-cranial 
carotid artery was measured bilaterally within three centimeters proximal and distal 
of the bifurcation and was automatically quantified with dedicated commercially 
available software (syngo calcium scoring, Siemens, Germany) (12). Calcification 
volumes in both carotid arteries were expressed in cubic millimeters (mm3) (13) 
(Figure 1). 
CHAPTER 2 
33 
 
Assessment of MRI-based calcification  
MRI imaging of the carotid arteries was performed on a single 1.5-T scanner (GE 
Healthcare, Milwaukee, WI, USA) with a dedicated bilateral phased-array surface coil 
(Machnet, Eelde, The Netherlands). The high-resolution images were obtained using 
a standardized protocol (14). First, both carotids were identified by means of two-
dimensional (2D) time-of-flight MR angiography. Second, high-resolution MRI 
sequences were planned to image the carotid bifurcations on both sides. These 
sequences consisted of four 2D sequences in the axial plane, namely a proton density 
weighted (PDw)-fast spin echo (FSE)-black blood (BB) sequence (in-plane resolution 
130/160 x 130/128 = 0.8 x 1 cm); a PDw-FSE-BB with an increased in-plane resolution 
Figure 1 Example of calcification in the left carotid artery bifurcation (indicated by the 
red star) on CT (left image) and on MRI (middle image; PDw-FSE-BB sequence, and right 
image; magnitude image of the 3D-phase contrast sequence). 
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(in-plane resolution 130/224 x 130/160 = 0.5 x 0.8 cm); a PDw-echo planar image 
(EPI) sequence (in-plane resolution 130/160 x 70/160 = 0.8 x 0.4 cm); and a T2w-EPI 
sequence (in-plane resolution 130/160 x 70/160 = 0.8 x 0.4 cm). Additionally, we 
performed two 3D sequences, namely a 3D-T1w-gradient echo (GRE) sequence (in-
plane resolution 180/192 x 180/180 = 0.9 x 1 cm), and a 3D phased-contrast MR 
angiography (in-plane resolution 180/256 x 180/128 = 0.7 x 1.4 cm) (supplementary 
table 3). The total scanning time was approximately 30 min (14). Calcification was 
evaluated bilaterally within three centimeters proximal and distal of the bifurcation 
(12). All calcification measurements on MRI were performed by one trained physician 
under the supervision of an experienced neuroradiologist. We performed an intra- 
and inter-observer reproducibility analysis on a random set of 30 MRI examinations. 
The intra- and inter-agreement was very good [Cohens’ Kappa: 0.91 (95% CI 0.82-
0.99) and 0.94 (95% CI 0.86-0.99)], respectively. We defined calcification as a 
hypointense region in the plaque on all sequences. We manually annotated and 
segmented calcification in all plaques using a standardized approach. First, we pre-
processed all images using a method that has been described extensively before (15). 
This starts with a bias correction to reduce the intensity inhomogeneity characteristic 
in MRI (15). Subsequently, the carotid artery in all images was rigidly registered to 
the black-blood image space using the Elastix tool (15). For the registration of the 
sequences, a Region of Interest (ROI) around the artery in black blood was used. This 
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ROI was obtained semi-automatically by uniformly growing an extracted carotid 
artery centerline, which requires three marked seed points at the common, internal 
and external parts of the artery (15). Then calcification was manually delineated in 
every consecutive slice using an annotation tool developed in Mevislab (MeVisLab, 
MeVis Medical Solutions AG). Fourth, the total volume of calcification was calculated 
by counting the number of voxels within the annotated areas and multiplying this by 
the voxel volume (Figure 1). This provided volumes of calcification in cubic 
millimeters. 
Assessment of history of stroke 
At study entry, all participants were interviewed, and a history of stroke was assessed. 
Moreover, after enrollment, all participants are continuously followed for the 
occurrence of stroke (16). All potential stroke events were reviewed by research 
physicians and verified by an experienced stroke neurologist (17). At the time of CT 
scan, 38 participants had suffered a prior stroke (16).  
Statistical analysis 
Due to skewed distributions of the calcification data, we used natural log (Ln) 
transformed values after we added 1.0 mm3 to the non-transformed data in order to 
deal with calcification scores of zero (Ln (calcification volume +1.0 mm3)) (16). Our 
analysis strategy consisted of four steps. First, we investigated the correlation of CT-
based calcification volumes with MRI-based calcification volumes using Spearman’s 
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correlation coefficient. Second, we used linear regression to assess the relation 
between CT-based and MRI-based calcification volumes while adjusting for the time 
interval between the scans. Given the substantial time interval between the CT and 
MRI examinations, we furthermore performed a sensitivity analysis in which we 
analyzed the correlation between CT-based and MRI-based calcification volumes 
only for those persons with an interval equal or less than 3 years (n = 128). We 
performed post-hoc sensitivity analysis while adjusting for CT-scanner type also. 
Third, we assessed the agreement between CT-based and MRI-based calcification 
volumes using a Bland-Altman analysis. Fourth, as a proof-of-principle, we 
investigated the association of CT-based and MRI-based calcification volumes (per 
1-SD increase) related with a history of stroke using logistic regression while 
adjusting for age, sex and the time interval between CT and MRI, and studied whether 
the results were comparable for both modalities All analyses were carried out using 
IBM SPSS Statistics version 21 (International Business Machines Corporation, 
Armonk, New York). 
RESULTS 
Table 1 shows the baseline characteristics of the study population. The mean age of 
participants at the time of CT examination was 68.1 years (SD: 6.1 years). There were 
41.5% female participants. We found no calcification in 60 participants (8.8%). There 
were no instances in which calcification was found on either CT or MRI and not on 
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the other modality. The mean Ln-transformed calcification volume for CT was 3.98 
mm³ (SD: 1.86 mm³), and 2.70 mm³ (SD: 1.36 mm³) for an MRI. 
Table 1 Baseline characteristics of study participants 
Sample size 684 
Woman 41.5% 
Age, years at CT scan 68.8±6.1 
Age, years at MRI scan 74.2±6.1 
CT calcification volumes, mm3* 3.98±1.87* 
MRI calcification volumes, mm3* 2.70±1.37* 
Smoking (current) 40.2% 
Systolic blood pressure (mm/Hg) 146.81±19.46 
Diastolic blood pressure (mm/Hg) 79.84±10.85 
Diabetes Mellitus 13.3% 
Serum total cholesterol (mmol/L) 5.6±0.9 
HDL cholesterol (mmol/L) 1.4±0.3 
Antihypertensive medication use 37.7% 
Statin medication use 31.1% 
Stroke events 5.6% 
Values are means with standard deviations for continuous variables and 
percentages for dichotomous or categorical variables. 
* Ln-transformed volumes (Ln (calcification volume+1mm3)). 
Abbreviation: CT = computed tomography, HDL = high-density lipoprotein, MRI = 
magnetic resonance imaging. 
We found a strong correlation between CT and MRI calcification volumes 
(Spearman’s correlation coefficient:0.86) (Figure 2, supplementary table 1, and 
supplementary table 2). This correlation was similar when we investigated the left 
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and right side separately (supplementary table 1). After performing linear regression 
with adjustment for the time interval between the CT and MRI scan, the prominent 
relation between CT-based and MRI-based calcification volumes remained present 
[beta per 1-SD increase in CT-based calcification volume: 0.65 (95% confidence 
interval (CI): 0.63–0.68)]. After performing the analyses in those persons with a time 
interval between the scans of less or equal to 3 years, the association between CT-
based and MRI-based calcification volumes was similar [beta per 1-SD increase in 
CT-based calcification volume: 0.65 (95% CI: 0.58–0.72)]. Adjustment for CT-scanner 
type did not influence the results (data not shown). 
Figure 2 Scatter plot of Ln-transformed CT-based and MRI-based calcification volumes, 
indicating a positive correlation between both detected and quantified calcification 
volumes. 
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Figure 3 shows the Bland-Altman plot for the relation between the absolute 
differences in Ln-transformed calcification volumes and the mean of the two 
measurements of 1.27 mm3 (standard deviation: 0.92). We found that the CT-based 
calcification volumes were consistently larger than those obtained from MRI. 
When investigating the relationship between calcification and a history of stroke, we 
found that both CT-based and MRI-based calcification volumes were associated with 
a history of stroke [CT - odds ratio per 1-SD increase: 1.52 (95% CI: 1.00–2.30), MRI – 
odds ratio per 1-SD increase: 1.47 (95% CI: 1.01–2.14)] (Table 2). 
Figure 3 Bland-Altman plot of the difference of CT-based and MRI-based Ln-
transformed total calcification volumes, with a mean absolute difference (bold continues 
line) and 95% confidence interval of mean differences (dashed lines). 
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Table 2 Association of calcification volumes with stroke  
                                                        Odds ratio (95%CI)                 p-value 
Model 1   
CT calcification volumes 1.63 (1.09-2.46) 0.01 
MRI calcification volumes 1.55 (1.07-2.24) 0.01 
Model 2   
CT calcification volumes 1.52 (1.00-2.30) 0.04 
MRI calcification volumes 1.47 (1.01-2.14) 0.04 
Model 1 - scan time difference. Model 2 –adjusted for age, sex and scan time 
difference. Values represent odd ratios with 95% CI per 1 standard deviation 
increase in calcification volumes.  
Abbreviation: CT = computed tomography, MRI = magnetic resonance imaging. 
  
DISCUSSION 
In this large population-based sample of persons with subclinical atherosclerosis, we 
found that CT-based and MRI-based volumes of carotid artery calcification are highly 
correlated, but MRI-based calcification is systematically smaller than those obtained 
with CT. Despite this difference, both provide comparable information with regard to 
a history of stroke.  
We found that CT-based and MRI-based calcification volumes were highly 
correlated. Yet, we also found that the volumes measured with MRI were 
systematically smaller than those measured on CT. This was especially interesting in 
light of the fact that the MRI was performed on average 4 years later than the CT. 
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Given that our scanning protocol on CT was specifically designed for the visualization 
of vascular calcification combined with that CT is currently the gold standard for the 
assessment calcification, it is likely that with MRI the amount of calcification is 
systematically underestimated (6). The reason for this could the differences between 
CT-based and MRI-based calcification volume may be explained by differences in 
image analysis to a certain extent. Additionally, differences in spatial resolution 
between CT and MRI might be a potential explanation for this difference. In this light, 
it is important to note that CT images were analyzed automatically using dedicated 
commercially available software, whilst MRI images were analyzed manually for the 
presence and amount of calcification. To our knowledge, there are no studies that 
have compared CT and MRI on the detection and quantification of carotid artery 
using a non-invasive population-based approach. Previous research performed on 
the comparison between CT and MRI in 50 patients with recent TIA or minor stroke, 
demonstrated a correlation between CT-based and MRI-based calcification volumes 
of the only p: 0.55 (18). We demonstrate that with the use of dedicated MRI-multi-
sequences for the detection of calcification the correlation between CT-based and 
MRI-based calcification volume is substantially improved. Finally, another important 
topic to consider with regard to the difference between CT and MRI is the blooming 
effect of calcifications which is known to occur on CT (19). Especially for calcifications 
with very high Hounsfield units, a gradient over multiple adjacent pixels is necessary 
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to reach a low Hounsfield unit. This effect may lead to slight overestimation of the 
calcification area. On the other hand, MRI is known to underestimate the amount of 
calcification, because a certain amount of calcification is required before the MR-
signal disappears. In this context, it is important to acknowledge that possible micro-
calcifications in the atherosclerotic plaque may be missed (20). 
As a proof of principle, we investigated the association of CT-based and MRI-based 
calcification with a history of stroke and found that both related to this outcome with 
comparable effect estimates. We chose history of stroke because the relationship 
between carotid artery calcification and stroke has been well-established (16, 21) 
(22). Importantly, despite the fact that MRI systematically underestimates the amount 
of calcification compared to CT, we found comparable risk estimates for CT-based 
and MRI-based calcification volumes with respect to a history of stroke. This suggests 
that when assessing clinical outcomes, the value of MRI-based calcification is similar 
to that of CT. 
Our findings have implications that should be considered in the choice for MRI or CT 
for the assessment of vascular calcification. First, while assessing atherosclerosis with 
MRI it is directly possible to visualize other plaque characteristics in addition to 
calcification, including intra-plaque hemorrhage and lipid-rich necrotic core which 
provide unique additional information on the disease. Second, MRI has the major 
advantage over CT that it does not involve harmful radiation exposure. Third, the 
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systematic underestimation of calcification on MRI may pose a problem, specifically 
in situations where one is particularly interested in the exact amount of calcification. 
Fourth, drawbacks of MRI, in general, are its absolute contraindications (i.e. metal 
objects in the body), and the fact that MRI is more time-consuming, more expensive 
and less widely available than CT. Taken together, the pros and cons of both imaging 
modalities should be carefully considered for all research and clinical applications 
involving the assessment of vascular calcification. 
The strengths of our study include the relatively large sample size of community-
dwelling individuals, all with varying degrees of carotid atherosclerosis, and the 
standardized assessment of calcification volumes on both modalities. Yet, some 
limitations should also be taken into account of which the first is the time interval 
between the CT scan and the MRI scan, with a mean interval of 4.9 years. We 
acknowledge that the interscan interval represents a potential limitation of the 
current study and that during this interval there may have been slight changes in 
plaque composition. Yet, we would like to emphasize that in all instances the CT-
scan was made before the MRI-scan and that calcification is a plaque component 
that generally remains present and shows only very slow progression over time (23, 
24). Therefore, it seems unlikely that the amount of calcification at the time of MRI 
would differ substantially from that at the time of the CT. This is further supported 
by the fact that adjustment for the time interval did not change the results; and 
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secondly by our finding that MRI volumes were consistently estimated somewhat 
smaller than CT volumes, whereas a large influence of the time interval would induce 
an opposite difference. Another potential limitation is that we used two types of 
MDCT scanners (16-slice and 64-slice) to assess calcification. Yet, adjustment for 
scanner-type did not change the association. 
CONCLUSION 
In summary, CT-based and MRI-based volumes of carotid artery calcification are 
highly correlated, but MRI-based calcification is systematically smaller than those 
obtained with CT. Despite this difference, both provide comparable information with 
regard to a history of stroke. 
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Supplementary Table 1 Relation between calcification volume on CT and MRI 
 MRI left carotid MRI right carotid MRI total volumes 
CT left carotid 0.77   
CT right carotid  0.78  
CT total volumes   0.86 
Correlation is significant at the 0.01 level (2-tailed). 
Abbreviation: CT = computed tomography, MRI = magnetic resonance imaging. 
 
 
Supplementary Table 2 Relation between calcification volume on CT and MRI, 
between the subjects with <3 years and >3 years difference on CT and MRI scans. 
 
MRI <3 years 
 n=128 
MRI >3 
n=556 
MRI total volumes 
n=684 
CT <3 years  0.79   
CT >3 years  0.87  
CT total volumes   0.86 
Correlation is significant at the 0.01 level (2-tailed). 
Abbreviation: CT = computed tomography, MRI = magnetic resonance imaging. 
CHAPTER 2 
52 
Supplementary table 3 Parameters of the MRI Protocol 
 2-D 3-D* 
 FSE-BB EPI PC-MRA GRE  
 PDw PDw T2w  T1w 
 Thin 
slice 
High 
Resolution 
    
TE, (ms) 9.8 12.7 24.3 60 4.3 1.8 
TR, (ms) 4800 2000 12000 12000 13 15.7 
ETL 6 4 - - - - 
Field of 
View, (cm) 
13x13 13x13 13x7 13x7 18x18 18x18 
Matrix 160x128 224x160 160x160 160x160 256x128 192x180 
Slice 
thickness, 
(mm) 
0·9 1·2 1·2 1·2 1·0/0·5† 1·0/0·5† 
No. of 
slices 
51 19 41 41 26/52 124/248 
NEX 2 3 20 25 1 1 
Scan time, 
(min.sec) 
3·36 4·04 4·00 5·00 6·13 6·02 
FSE-BB indicates Fast Spin Echo Black Blood; EPI, Echo Planar Imaging; PC-
MRA, Phased-Contrast Magnetic Resonance Angiography; GRE, Gradient 
Recalled Echo; PD, proton density; TR, repetition time; TE, echo time; ETL, echo 
train length; NEX, No. of excitations; 2-D, two-dimensional; 3-D, three-
dimensional. 
* = Axial images are reconstructed from the 3-D volume 
† = Images are interpolated from 1·0 mm to 0·5 mm 
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Chapter 3.1  
Serum insulin levels are associated with 
vulnerable plaque components in the 
carotid artery 
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ABSTRACT AND KEYWORDS 
Background 
To investigate the association between fasting serum insulin and glucose levels with 
atherosclerotic plaque composition in the carotid artery. Impaired insulin and 
glucose levels are implicated in the etiology of cardiovascular disease, however, their 
influence on the formation and composition of atherosclerotic plaque remains 
unclear. 
Methods  
In 1740 participants (mean age 72.9 years, 46% women, 14.4 % diabetes mellitus) 
from the population-based Rotterdam Study, we performed carotid MRI to evaluate 
the presence of calcification, lipid core, and intraplaque hemorrhage in carotid 
atherosclerosis. All participants also underwent blood sampling to obtain 
information on serum insulin and glucose levels. Using logistic regression models, 
we assessed the association of serum insulin and glucose levels (per standard 
deviation (SD) and in tertiles) with the different plaque components, while adjusting 
for sex, age, intima-media thickness, and cardiovascular risk factors. Results 
High serum insulin levels were associated with the presence of intraplaque 
hemorrhage [adjusted odds ratio (OR): 1.32 (95% confidence interval (CI) 1.01–1.75)] 
and with a lower frequency of lipid core [adjusted OR: 0.69 (95%CI: 0.54–0.88)]. We 
found no association with the presence of calcification. Sensitivity analyses restricted 
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to individuals without diabetes mellitus yielded similar results. No associations were 
found between serum glucose levels and any of the plaque components. 
Conclusions 
High serum insulin levels are associated with the presence of intraplaque 
hemorrhage, and with a lower frequency of lipid core in carotid atherosclerosis. 
These findings suggest a complex role for serum insulin in the pathophysiology of 
carotid atherosclerosis and in plaque vulnerability. 
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INTRODUCTION 
Dysregulations in insulin and glucose metabolism, the pathophysiological 
underpinnings of diabetes mellitus, are associated with an increased risk of 
cardiovascular disease due to the accelerated accumulation of atherosclerosis (1, 2). 
Despite abundant evidence for a role of diabetes in the pathophysiology of 
atherosclerosis and clinical cardiovascular events, insights into the contribution of 
early disruptions in serum levels of insulin and glucose on the development of 
atherosclerosis remain scarce. Moreover, levels of serum insulin and their 
atherogenic properties are even conflicting (3-5).  
Another important topic of interest within the field of atherosclerosis, for which the 
role of serum levels of insulin and glucose are even more elusive, pertains to plaque 
composition. Plaque composition is directly related to the chances of a plaque to 
rupture and potentially result in clinical cardiovascular events (6-9). The vulnerability 
of a plaque to rupture is assessed by evaluation of the presence of vulnerable, non-
calcified plaque components such as lipid core or intraplaque hemorrhage (9), and 
the presence of calcification, which is regarded as a more plaque-stabilizing 
component (3-5). In-vivo visualization of the atherosclerotic plaque and its 
components can be non-invasively accomplished by magnetic resonance imaging 
(MRI) (10). 
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Against this background, we investigated the association between insulin and 
glucose levels with atherosclerotic plaque composition in the carotid artery in a large 
population-based cohort of subjects with subclinical atherosclerosis.  
METHODS 
Study population 
The Rotterdam Study is a prospective population-based cohort (11). Between 2007 
and 2012 participants with carotid atherosclerosis were invited to undergo an MRI 
scan of the carotid arteries. Participants were selected for MRI based on the results 
of carotid artery ultrasound examination (intima-media thickness ≥2.5 mm in one or 
both carotid arteries) performed in all participants of the Rotterdam Study. From the 
2666 invited participants, 272 refused to participate, and another 363 did not 
undergo MRI scan due to claustrophobia (n=57), physical limitations (n=191), and 
MRI contraindication (n=115). From the remaining 1982 participants that underwent 
MRI scan, 242 were excluded due to bad image quality (n=95), the absence of plaque 
(n=41), or incomplete examinations due to claustrophobia during scanning (n=106). 
Hence, 1740 participants were included in the analyses. The Rotterdam Study 
complies with the Helsinki Declaration and has been approved by the Medical Ethics 
Committee of the Erasmus MC and by the Dutch Ministry of Health, Welfare and 
Sports, implementing the “Wet Bevolkings Onderzoek: ERGO (Population Screening 
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Act: Rotterdam Study)”. All participants provided written informed consent to 
participate in the study and to obtain information from their treating physicians. 
Carotid scanning and analysis of plaque components 
A magnetic resonance 1.5 Tesla scanner (GE Healthcare, Milwaukee, WI, USA) with a 
dedicated bilateral phased-array surface coil (Machnet, Eelde, the Netherlands) was 
used to perform bilateral multisequence imaging of the carotid arteries, with a 
standardized scanning protocol, that required an approximate total scanning time of 
30 minutes. Details of the scanning protocol, reading procedure, and reproducibility 
is described in detail elsewhere (12, 13). Two independent readers, with three years 
of experience visually evaluated the carotid artery images for the presence of three 
plaque components, namely intraplaque hemorrhage (IPH), lipid core, and 
calcification. IPH was defined as the presence of a hyperintense region in the 
atherosclerotic plaque on 3D-T1w-GRE. Lipid core presence was defined as a 
hypointense region, not classified as IPH or calcification, in the plaque on PDw-FSE 
or PDw-EPI and T2w-EPI images or a region of relative signal intensity drop in the 
T2w-EPI images compared with the PDw-EPI images. Calcification was defined as the 
presence of a hypointense region in the plaque on all sequences (14). Subjects were 
recorded as positive for the presence of any plaque component if the component 
was identified in one or both carotid arteries. To assess the intra-scan variability, 40 
participants underwent a second MRI scan (average time between scans 15 ± 9 days). 
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For interobserver reproducibility analyses, random MRI examinations were selected 
(n = 50) and read by a second observer. Intra-scan and interobserver agreement were 
calculated by using Cohens’ Kappa statistics. The intra-scan agreement was good for 
all measurements. The Kappa value for the presence of IPH was 0.95 (95% CI 0.88–
0.99); for lipid core 0.85 (95% CI 0.74–0.96) and for calcification 0.91 (95% CI 0.82–
0.99). The interobserver agreement was good for all measurements. The Kappa value 
for IPH was 0.86 (95% CI 0.72–0.99); for lipid core 0.86 (95% CI 0.72–0.99) and for 
calcification 0.94 (95% CI 0.86–0.99) (13). 
Assessment of fasting insulin and glucose levels 
The venous blood samples were taken, after overnight fasting from all participants 
at the research center and stored at −80°C in a number of 5-mL aliquots. Serum 
fasting glucose levels were determined by using the glucose hexokinase method 
within 1 week after sampling (15). Serum fasting insulin level was determined in 
samples that had been kept frozen and were measured on a Roche Modular Analytics 
E170 analyzer (Roche Diagnostics GmbH, Mannheim, Germany) by 
electrochemiluminescence immunoassay technology. This assay does not cross-react 
with proinsulin or C-peptide. The intraassay repeatability showed a coefficient of 
variation of 1.0%. The day-to-day variation of the assay (i.e., intermediate precision) 
yielded a coefficient of variation of 3.6%. These numbers indicate the excellent 
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reliability of the insulin assay in our study (16). The blood measurements were made 
for all participants at study entry and the mean time interval between blood 
measurements and carotid MRI scan was 7.9 years (standard deviation of 4.0 years). 
Other risk factors in the Rotterdam Study 
The information about other cardiovascular risk factors as relevant covariables was 
obtained by interview, physical examination, and blood sampling between the years 
1998 and 2008 (11). Diabetes mellitus was defined as fasting blood glucose >6.9 
mmol/L, nonfasting glucose >11.0 mmol/L, or use of glucose-lowering medication. 
Systolic and diastolic blood pressure was measured using a random-zero 
sphygmomanometer on the right arm and two measurements were averaged for the 
analysis. Smoking status was assessed by interview and categorized into never, past, 
and current smoking. Body mass index (BMI) was calculated based on the weight in 
kilograms divided by height in meters squared. Total cholesterol and high-density 
lipoproteins (HDL) levels were measured using standard laboratory techniques. The 
information on the use of antihypertensive medication and lipid-lowering 
medication was obtained from pharmacy records (11). History of stroke or coronary 
heart disease (CHD) was self-reported at study entry and verified by clinical data from 
the medical records or the occurrence during study follow-up but before the time of 
carotid MRI scanning.  
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Statistical analysis 
The distribution of continuous and categorical variables was described using means 
(standard deviations [SD]), medians (interquartile ranges [IQRs]), or percentages. We 
performed a natural logarithmic transformation to normalize the distributions of 
serum insulin and glucose. To investigate the association between fasting insulin and 
glucose levels with intraplaque hemorrhage (IPH), lipid core, and calcification, a 
three-step statistical analysis approach was used. First, we investigated the 
association between fasting insulin and glucose levels with the presence of each 
component in one or both carotid arteries using logistic regression models. In model 
1, adjusted for sex, age, intima-media thickness and the time difference between 
insulin and glucose measurements and MRI scan. In model 2, additionally adjusted 
for smoking, serum high-density lipoprotein, serum total cholesterol, systolic and 
diastolic blood pressure, body mass index, use of antihypertensive medication, and 
insulin or glucose levels, dependent on the determinant under investigation. In 
model 3, additionally adjusted for the use of lipid-lowering medication (13), vitamin 
K antagonists and antiplatelet agents (17). Second, we categorized serum insulin and 
glucose levels into tertiles and investigated the association of tertiles of insulin and 
glucose (lowest tertile was used as the reference category) with carotid plaque 
components using regression model 1. Third, we performed the following three 
sensitivity analyses.  In the first analysis, we investigated all above-mentioned 
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associations only in participants that had their MRI-scan and blood measurements 
within one year in order to assess the potential effect of the time delay between the 
measurements. In the second analysis, we reassessed all associations in participants 
that were free of diabetes mellitus at the time of the MRI. In the third analysis, we 
stratified all analyses for sex to investigate whether associations are different 
between males and females. Additionally, we investigated the association between 
serum insulin and glucose and intima-media thickness using regression models. All 
analyses were carried out using IBM SPSS Statistical package version 21 (Chicago, IL, 
USA). 
RESULTS 
Table 1 shows the population characteristics at the MRI scan. The mean age of the 
population was 72.9 years (9.1 years) and 46.0 percent were women. A total of 251 
(14.4%) participants were diagnosed with diabetes mellitus at baseline. The median 
(IQR) fasting insulin level was 74 (50–98) pmol/L and the median (IQR) fasting glucose 
level was 5.6 (5.2–6.0) mmol/L. 
Associations between fasting insulin and glucose levels with the different plaque 
components are summarized in Table 2. We found that higher fasting insulin levels 
were associated with the presence of intraplaque hemorrhage (fully adjusted odds 
ratio (OR) per 1-SD increase in insulin level: 1.39 [95% confidence interval (CI): 1.09–
1.76]) (Table 2, model 2). Further adjustment for antithrombotic treatment increased 
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the estimate and empowered the association (OR per 1-SD increase: 1.43 [95% 
confidence interval (CI): 1.14–1.81]) (Table 2, model 3). Higher fasting insulin levels 
also related to a lower frequency of lipid core (fully adjusted OR per 1-SD increase in 
insulin level: 0.88 [95% CI: 0.72–1.09]) (Table 2, model 3). We found no association 
between fasting glucose levels with any of the plaque components. 
When investigating tertiles of insulin and glucose levels, we found that the high 
insulin level tertile was associated with a higher frequency of intraplaque 
hemorrhage (adjusted OR of highest versus lowest tertile: 1.32 [95% CI: 1.01–1.75]) 
and a lower frequency of lipid core (adjusted OR of highest versus lowest tertile: 
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Table 1  Baseline characteristics of the study population (n=1740) 
Characteristics Insulin ≤57 Insulin 58–89 Insulin >90 P-value All 
Number in category 587 615 538  1740 
Age, years (SD) 74.0±8.8 73.4±9.1 71.1±9.4 <0.001 72.9±9.1 
Women, % 48.9 47.2 41.4 0.03 46.0 
Smoking, current % 43.3 41.1 42.9 0.41 42.4 
Diabetes mellitus, % 8.2 11.4 24.7 <0.001 14.4 
Fasting glucose, mmol/L (SD) 5.3 (5.0–5.7) 5.6 (5.2–5.9) 5.9 (5.4–6.5) <0.001 5.6 (5.2–6.0) 
Fasting insulin, pmol/L 44 (35–51) 75 (66–85) 121(100–165) <0.001 74(50–98) 
Systolic blood pressure, mm/Hg (SD) 144±20 147±20 144±20 0.02 145±20 
Diastolic blood pressure, mm/Hg (SD) 79±10 81±10 81±11 0.001 80±10 
BMI, kg/m2 (SD) 25.7±3.0 27.1±3.1 29.2±3.7 <0.001 27±3.5 
Total cholesterol, mmol/L (SD) 5.6±1.0 5.7±1.0 5.5±1.0 0.004 5.6±1.0 
HDL cholesterol, mmol/L (SD) 1.5±0.3 1.4±0.3 1.2±0.3 <0.001 1.4±0.3 
Antihypertensive medication, % 32.0 36.6 50.4 <0.001 39.3 
Statin use, % 25.6 28.6 33.3 0.02 29.0 
Vitamin K antagonists, % 5.8 5.7 5.2 0.90 5.6 
Antiplatelet agents; % 27.6 26.5 28.4 0.76 27.5 
Intima-media thickness, mm 3.2±0.6 3.2±0.6 3.2±0.7 0.77 3.2±0.6 
Degree of stenosis, (%) 
12.3 (0.0–
25.9) 
14.5 (0.0–26.4) 15.2 (0.0–28.0) 0.16 14.5 (0.0–26.8) 
History of stroke, % 4.6 7.2 6.5 0.02 6.3 
History of coronary heart disease, % 12.8 10.1 11.5 0.01 11.4 
Presence of calcification, % 85.7 80.2 81.0 0.02 82.3 
Presence of lipid core, % 47.2 45.5 38.8 0.01 44.0 
Presence of intraplaque hemorrhage, % 32.5 35.9 35.5 0.41 34.7 
Values are means with standard deviations and median (interquartile ranges) for continuous 
variables and percentages for dichotomous or categorical variables. P-values were derived by 
Fisher’s exact test or analysis of variance (ANOVA).  
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Table 2  Association serum insulin and glucose levels with carotid artery plaque 
composition (n=1740) 
Insulin   
IPH 
OR (95%CI) 
 
Lipid core 
OR (95%CI) 
 
Calcification 
OR (95%CI) 
Model 1  1.27 (1.05–1.55)  0.76 (0.63–0.90)  0.93 (0.74–1.16) 
Model 2*  1.39 (1.09–1.76)  0.88 (0.72–1.09)  1.05 (0.80–1.38) 
Model 3  1.43 (1.14–1.81)  0.88 (0.72–1.09)  1.05 (0.80–1.38) 
Glucose       
Model 1  1.04 (0.55–1.96)  0.51 (0.29–0.91)  1.19 (0.58–2.47) 
Model 2†  0.49 (0.20–1.21)  1.08 (0.49–2.37)  1.22 (0.44–3.34) 
Model 3  0.48 (0.19–1.19)  1.10 (0.50–2.41)  1.18 (0.43–3.24) 
Odds ratio (OR), given with a 95% confidence interval (CI), express the relationship between 
serum insulin and glucose (per SD increment) with intraplaque hemorrhage (IPH), lipid core 
and calcification. Model 1 = adjusted for sex, age, intima-media thickness and the time 
difference between insulin and glucose measurements and MRI scan. Model 2 = model 1 + 
smoking, high-density lipoprotein, total cholesterol, systolic and diastolic blood pressure, 
body mass index, use of antihypertensive medication and *glucose or †insulin levels. Model 3 
= model 2 + use of lipid-lowering medication, vitamin K antagonists and antiplatelet agents.  
0.69 [95% CI: 0.54–0.88]) compared to the low tertile (Figure 1). Again, for glucose, 
we did not find any association with the various plaque components (Figure 2). 
When restricting analyses only to participants who had both measurements (insulin 
and glucose measurements and MRI scan) within one year (n=212), the results were 
in similar trend (Table S1). Similarly, the results did not change when we excluded 
participants with a diagnosis of diabetes mellitus at the time of MRI (n=1489) (Table 
S2). Furthermore, after stratifying the analyses by sex similar effect estimates, 
between males and females, for the association of serum insulin levels with IPH and 
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lipid core. Whereas no association was observed for calcification in both sexes. Also, 
when assessing the relationship between glucose and plaque components no 
association was observed in either sex (Table S3). Moreover, when assessing the 
relationship between serum insulin or glucose and carotid intima-media thickness 
no association was found (Table S4). 
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Figure 1  Association of serum insulin levels (tertiles) with plaque composition in the carotid artery. 
Values on the x-axis represent the odds ratios and 95% confidence interval. The values are adjusted 
for sex, age, and intima-media thickness. Statistics was performed using logistic regression using total 
sample of subjects n=1740. P-trend over categories of insulin for intraplaque hemorrhage was 0.04, 
for lipid core was 0.003 and for calcification was 0.32.  
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Figure 2  Association of serum glucose levels (tertiles) with plaque composition in the carotid artery. 
Values on the x-axis represent the odds ratios and 95% confidence interval. The values are adjusted 
for sex, age, and intima-media thickness. Statistics was performed using logistic regression using 
total sample of subjects n=1740. P-trend over categories of glucose for intraplaque hemorrhage 
was 0.87, for lipid core was 0.33 and for calcification was 0.81. 
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DISCUSSION 
In this large population-based study of subjects with subclinical carotid 
atherosclerosis, we observed that higher fasting serum insulin levels were associated 
with the presence of intraplaque hemorrhage and a lower frequency of lipid core 
within the carotid atherosclerotic plaque. We did not find an association between 
fasting glucose levels and any of the carotid plaque components.  
Until now, most of the evidence linking insulin and glucose to atherosclerosis comes 
from studies in which atherosclerotic cardiovascular clinical endpoints, such as 
ischemic heart disease or ischemic stroke, were investigated (18-20). 
Hyperinsulinemia was found to increase the risk of ischemic heart disease among 
4637 middle-aged men from the Quebec Cardiovascular Study (18), and the risk of 
acute coronary and cerebrovascular events in 1521 men enrolled in Kuopio Ischemic 
Heart Disease Risk Factor Study (19). Our results extend on these findings by showing 
that preclinical changes in serum insulin levels relate to a more vulnerable 
composition of the carotid atherosclerotic plaque. More specifically, we 
demonstrated that high serum insulin levels, especially relate to the presence of 
intraplaque hemorrhage, the plaque component which is regarded as the most 
vulnerable (21). Similarly, insulin was found to increase intraretinal hemorrhage and 
extraretinal neovascularization in rats (22). Previous animal studies described insulin 
to play a pleiotropic effect on the vascular system, through vascular endothelial 
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growth factor (VEGF), which plays a pivotal role in angiogenesis (22, 23). High levels 
of insulin increase the levels of VEGF, which in turn induce abnormal 
neovascularization that is prone to leakage and hemorrhage (22).  In addition, 
interestingly, we also found that high serum insulin levels related to a lower 
frequency of lipid core, which is generally also considered an indicator of unstable 
plaque. This finding may potentially be explained by the insulin lowering effect on 
plasma oxidized LDL/LDL cholesterol ratio (24).  
In contrast to high or low serum insulin levels, it may be speculated that physiological 
concentration levels (median levels 66–85 pmol/L) potentially behave protectively 
against atherosclerosis. Observations in our study showed that medium levels of 
serum insulin were not associated with any vulnerable plaque component, but were 
associated with a lower presence of calcification, which may support the hypothesis 
that medium levels of serum insulin have the protective effect (Figure 1). In the same 
line, a recent animal study examined the role of insulin in atherosclerotic plaque 
reported the protective effect of insulin on atherosclerosis (21). In this study, the 
insulin effect was tested on atherosclerosis in a mouse model, and insulin was found 
to decrease the plaque burden and increased plaque stability via nitric oxide synthase 
(NOS) mechanisms (21). Furthermore, it was found that insulin reduced macrophage 
accumulation, plaque necrosis, and increased collagen and smooth muscle cell 
accumulation (21). However, it seems that only disrupted levels of serum insulin, low 
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and high insulin levels, link serum insulin with atherosclerosis. Previously, animal 
studies demonstrated also that impaired insulin signaling by genetic modification 
accelerated atherosclerosis (25-27). 
Surprisingly, we found no effects on serum glucose levels in carotid plaque 
composition. In the context of glucose, our findings do not support previous reports 
that link higher glucose levels to an increased risk of vascular diseases (28). However, 
a recent meta-analysis of 102 prospective studies that investigated the relationship 
between fasting glucose levels and risk of vascular diseases concluded that glucose 
concentrations were non-linear and modestly associated with the risk of vascular 
diseases among individuals without diabetes (20), meaning that glucose levels below 
and higher than 7.0 mmol/L were associated with increased risk for coronary heart 
disease and ischemic stroke (20). 
In terms of clinical practice, our findings may have clinical implications given that 
these suggest that fasting serum insulin conveys information on the atherosclerotic 
plaque composition that may ultimately be used for risk stratification of patients in 
daily practice.  
The major strength of our study includes the largest population-based sample of 
individuals with subclinical carotid atherosclerosis and the MRI-based assessment 
carotid plaque composition. Given the accurate diabetes assessments within the 
Rotterdam Study, we were able to address for the first time the association between 
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subclinical variations of insulin and glucose levels with atherosclerotic disease. 
Nevertheless, our study should be interpreted in the context of some limitations. 
First, the cross-sectional study design limits us to draw causal inferences between 
fasting insulin and atherosclerotic plaque components. Second, in a substantial part 
of our study population, the time interval between insulin and glucose 
measurements and MRI scanning was more than 2 years. However, limiting our 
analyses to the subgroup of participants with available measurements of MRI and 
serum insulin levels in the same year did show different associations. 
CONCLUSION 
In conclusion, high serum insulin levels are associated with the presence of 
intraplaque hemorrhage, and with a lower frequency of lipid core in carotid 
atherosclerosis, suggesting that serum insulin may play a role in the vulnerability of 
carotid atherosclerotic plaque. Further studies are required to confirm our findings 
in a longitudinal design.
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Table S1   Association serum insulin and glucose levels with carotid artery plaque 
composition in the ≤ 1-year difference between MRI and insulin measurements 
(n=212) 
Insulin  
IPH 
OR (95%CI) 
 
Lipid core 
OR (95%CI) 
 
Calcification 
OR (95%CI) 
Model 1  1.50 (0.85–2.64)  0.41 (0.23–0.74)  0.98 (0.55–1.75) 
Model 2*  2.02 (0.97–4.19)  0.41 (0.20–0.84)  0.96 (0.45–2.06) 
Model 3  2.41 (1.11–5.21)  0.40 (0.20–0.83)  0.97 (0.45–2.11) 
Glucose       
Model 1  1.03 (0.20–5.44)  0.20 (0.36–1.08)  1.38 (0.25–7.58) 
Model 2†  0.22 (0.20–2.84)  0.49 (0.05–4.88)  0.22 (0.02–2.64) 
Model 3  0.16 (0.01–2.43)  0.52 (0.05–5.20)  0.21 (0.02–2.66) 
Odds ratio (OR), given with a 95% confidence interval (CI), express the relationship between 
serum insulin and glucose (per SD increment) with intraplaque hemorrhage (IPH), lipid core 
and calcification. Model 1 = adjusted for sex, age, intima-media thickness and the time 
difference between insulin and glucose measurements and MRI scan. Model 2 = model 1 + 
smoking, high-density lipoprotein, total cholesterol, systolic and diastolic blood pressure, 
body mass index, use of antihypertensive medication and *glucose or †insulin levels. Model 3 
= model 2 + use of lipid-lowering medication, vitamin K antagonists and antiplatelet agents. 
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Table S2 Association serum insulin and glucose levels with carotid artery plaque 
composition in individuals free of diabetes mellitus (n=1489) 
Insulin  
IPH 
OR (95%CI) 
 
Lipid core 
OR (95%CI) 
 
Calcification 
OR (95%CI) 
Model 1  1.32 (1.05–1.66)  0.78 (0.64–0.96)  0.98 (0.75–1.29) 
Model 2*  1.46 (1.12–1.90)  0.86 (0.68–1.09)  1.13 (0.82–1.56) 
Model 3  1.49 (1.14–1.95)  0.87 (0.69–1.11)  1.12 (0.81–1.54) 
Glucose       
Model 1  0.71 (0.20–2.57)  0.90 (0.30–2.67)  1.31 (0.32–5.38) 
Model 2†  0.40 (0.10–1.54)  1.85 (0.56–6.13)  0.92 (0.20–4.28) 
Model 3  0.41 (0.11–1.59)  1.86 (0.56–6.19)  0.94 (0.20–4.41) 
Odds ratio (OR), given with a 95% confidence interval (CI), express the relationship between 
serum insulin and glucose (per SD increment) with intraplaque hemorrhage (IPH), lipid core 
and calcification. Model 1 = adjusted for sex, age, intima-media thickness and the time 
difference between insulin and glucose measurements MRI scan. Model 2 = model 1 + 
smoking, high-density lipoprotein, total cholesterol, systolic and diastolic blood pressure, 
body mass index, use of antihypertensive medication and *glucose or †insulin levels. Model 3 
= model 2 + use of lipid-lowering medication, vitamin K antagonists and antiplatelet agents.  
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Table S3 Association serum insulin and glucose levels with carotid artery plaque 
composition stratified by sex 
Females 
(n=800) 
  
IPH 
OR (95%CI) 
 
Lipid core 
OR (95%CI) 
 
Calcification 
OR (95%CI) 
Insulin Model 1  1.16 (0.87–1.57)  0.72 (0.55–0.94)  0.95 (0.68–1.32) 
 Model 2  1.25 (0.87–1.79)  0.82 (0.60–1.13)  1.04 (0.70–1.56) 
 Model 3*  1.26 (0.88–1.81)  0.81 (0.58–1.12)  1.02 (0.67–1.54) 
Glucose Model 1  1.80 (0.61–5.32)  0.64 (0.24–1.72)  1.15 (0.33–4.08) 
 Model 2  1.13 (0.24–5.30)  3.84 (0.92–16.13)  2.27 (0.38–13.69) 
 Model 3†  1.11 (0.23–5.28)  4.19 (0.98–17.88)  2.42 (0.39–15.17) 
Males 
(n=940) 
  
IPH 
OR (95%CI) 
 
Lipid core 
OR (95%CI) 
 
Calcification 
OR (95%CI) 
Insulin Model 1  1.35 (1.04–1.74)  0.90 (0.68–1.17)  0.92 (0.67–1.24) 
 Model 2  1.52 (1.11–2.06)  0.93 (0.70–1.22)  1.08 (0.75–1.58) 
 Model 3*  1.57 (1.15–2.14)  0.93 (0.71–1.24)  1.07 (0.74–1.56) 
Glucose Model 1  0.74 (0.33–1.67)  0.46 (0.22–0.95)  1.18 (0.48–2.85) 
 Model 2  0.31 (0.10–0.98)  0.64 (0.24–1.71)  0.85 (0.25–2.88) 
 Model 3†  0.30 (0.09–0.96)  0.65 (0.24–1.72)  0.84 (0.25–3.14) 
Odds ratio (OR), given with a 95% confidence interval (CI), express the relationship between 
serum insulin and glucose (per SD increment) with intraplaque hemorrhage (IPH), lipid core 
and calcification. Model 1 = adjusted for age, intima-media thickness and the time difference 
between insulin and glucose measurements MRI scan. Model 2 = model 1 + smoking, high-
density lipoprotein, total cholesterol, systolic and diastolic blood pressure, body mass index, 
use of antihypertensive medication and *glucose or †insulin levels. Model 3 = model 2 + use 
of lipid-lowering medication, vitamin K antagonists and antiplatelet agents. 
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Table S4 Association serum insulin and glucose levels with intima-media thickness 
(n=1740) 
Insulin  Beta  95% CI  p-value 
Model 1   0.009  -0.048–0.066  0.75 
Model 2  -0.004  -0.071–0.063  0.91 
Model 3*   0.006  -0.061–0.072  0.87 
Glucose       
Model 1   0.034  -0.154–0.222  0.72 
Model 2  -0.012  -0.266–0.242  0.93 
Model 3†  -0.014  -0.267–0.238  0.91 
Effect size, given with a 95% confidence interval (CI), express the relationship between serum 
insulin and glucose (per SD increment) intima-media thickness. Model 1 = adjusted for sex, 
age and the time difference between insulin and glucose measurements and MRI scan. Model 
2 = model 1 + smoking, high-density lipoprotein, total cholesterol, systolic and diastolic blood 
pressure, body mass index, use of antihypertensive medication and *glucose or †insulin levels. 
Model 3 = model 2 + use of lipid-lowering medication, vitamin K antagonists and antiplatelet 
agents.  
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ABSTRACT  
Rationale: Sex steroids may play a role in plaque composition and in stroke 
incidence.  
Objectives: To study the associations of endogenous estradiol and testosterone 
with carotid plaque composition in elderly men and postmenopausal women with 
carotid atherosclerosis, as well as with risk of stroke in this population.  
Methods and Results: Data of 1023 postmenopausal women and 1124 men (≥45 
years) with carotid atherosclerosis, from prospective population-based Rotterdam 
Study, were available. At baseline, total estradiol (TE) and total testosterone (TT) 
were measured. Carotid atherosclerosis was assessed by ultrasound, whereas 
plaque composition (presence of calcification, lipid core and intraplaque 
hemorrhage) was assessed by MRI. TE and TT were not associated with calcified 
carotid plaques in either sex. TE was associated with presence of lipid core in both 
sexes (in women odds ratio (OR), 95% CI: 1.48 [1.02, 2.15], in men OR, 95% CI: 1.23 
(1.03, 1.46]), whereas no association was found between TT and lipid core in either 
sex. Higher TE (OR, 95% CI: 1.58 [1.03, 2.40]) and lower TT (OR, 95% CI: 0.82 [0.68, 
0.98]) were associated with intraplaque hemorrhage in women but not in men. In 
women, TE was associated with increased risk of stroke (hazard ratio (HR), 95% CI: 
1.98 [1.01, 3.88], whereas no association was found in men. TT was not associated 
with risk of stroke in either sex.  
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Conclusions: TE was associated with presence of vulnerable carotid plaque as well 
as increased risk of stroke in women, whereas no consistent associations were 
found for TT in either sex.  
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ABBREVIATIONS 
BMI= body mass index 
DHEA= dehydroepiandrosterone 
FAI= free androgen index 
HT= hormone therapy  
SHBG= sex hormone-binding globulin  
TE= total estradiol (17-β Estradiol) 
TSH= thyroid stimulating hormone 
TT= total testosterone 
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INTRODUCTION 
Ischemic stroke, a major cause of death and long-term disability among men and 
women, inflicts a considerable economic burden to society (1). Within the etiology 
of ischemic stroke, atherosclerotic disease of the carotid artery, and particularly 
plaque composition are important risk factors (2). Carotid atherosclerotic plaque 
can be composed of various components, such as a lipid pool (with/without 
necrosis), calcification, and intraplaque hemorrhage (3). Plaques that contain lipid 
deposits can lead to development of so-called vulnerable plaques in which 
hemorrhage can develop. This in turn can lead to plaque instability, further 
progress to rupture, ultimately precipitating embolism (4, 5) and subsequently 
increase risk of stroke (2). Sex differences have been observed in plaque 
composition as well as in stroke incidence (6). Stroke incidence is about 30% higher 
in men than in women (98). In line with this, women have higher rates of stable 
fibro-calcific atherosclerotic plaques, while plaques found in men tend to be more 
complex with higher rates of unstable lesions- intraplaque hemorrhage and 
presence of necrotic lipid core (7). Nevertheless, in women the risk for stroke 
roughly doubles during the 10 years after menopause (8). These sex- and 
menopause-differences in plaque composition and risk of stroke might be driven 
by endogenous sex hormones (9, 10). Experimental evidence suggests a direct 
action of estradiol on the vascular system, affecting many mechanisms that impact 
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plaque composition and occurrence of atherothrombotic ischemic stroke, including 
lipid metabolism, inflammation, oxidative stress, fibrinolysis, and thrombosis (11). 
Testosterone may slow down atherosclerosis through inhibiting carotid intima-
media thickening , atheroma formation (12) and immunomodulation of plaque 
development and stability (13). To date, no study has investigated the association 
between circulating estradiol, testosterone and plaque composition in human 
populations. Also, limited evidence exists on endogenous estradiol, testosterone 
and risk of stroke, and particularly in high risk populations such as subjects with 
presence of carotid atherosclerosis who are at increased risk of developing stroke 
(14).  
The aim of our study was to investigate the associations of endogenous estradiol 
and testosterone with carotid plaque composition in middle-aged and elderly men 
and postmenopausal women with carotid atherosclerosis, as well as with risk of 
stroke in this population.  
Methods and materials  
Study Population 
The Rotterdam Study (RS) is a prospective, population-based cohort study among 
individuals aged ≥ 45 in Ommoord municipality of Rotterdam, The Netherlands. 
The rationale and design of RS is described in detail elsewhere (15). In brief, all 
inhabitants of the Ommoord district aged 55 years or older were invited to 
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participate (n =10,215). At baseline (1990-1993), 7,983 participants were included 
(RS-I). In 2000, all persons living in the study district who had become 55 years of 
age (n=3011) were additionally enrolled (RS-II). A second extension of the cohort 
was initiated in 2006, in which 3,932 participants aged 45 years or older were 
included (RS-III). Follow-up visits were held every 3-5 years. The Rotterdam Study 
has been approved by the Medical Ethics Committee according to the Wet 
Bevolkingsonderzoek: ERGO (Population Study Act: Rotterdam Study), executed by 
the Ministry of Health, Welfare and Sports of The Netherlands. All participants gave 
informed consent to participate in the study and to obtain information from 
treating physicians and pharmacies, separately. The present study used data from 
the third visit of the first cohort (RSI-3, year 1997-1999) and the baseline 
examinations of the second (RSII-1, year 2000-2001) and third cohort (RSIII-1, year 
2006-2008). 
Population for Analyses 
Sex steroids and Plaque Composition  
All subjects (n=2,666) diagnosed with carotid atherosclerosis by carotid artery 
ultrasound (intima-media thickness > 2.0 mm in one or both carotid arteries) were 
invited to magnetic resonance imaging (MRI) of carotid arteries. Subjects were not 
examined due to various reasons (n=790): MRI contraindications (n=115), physical 
limitations (n=191), claustrophobia (n=163), refusal to participate (n=272), and loss 
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to follow-up (n=49). Of the remaining 1876 participants, 95 were excluded due to 
poor image quality, 41 because of absence of carotid plaque bilaterally, 215 
subjects did not have information on TE, TT levels and 45 women previously used 
HT or did not have information on HT use. Therefore, 645 postmenopausal women 
and 835 men were included in final analysis for the association of sex steroids with 
plaque composition and subsequent carotid features (Figure 1).  
Figure 1. Flowchart of study participants 
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Sex Steroids and Stroke Incidence 
From 2,666 participants diagnosed with carotid atherosclerosis, 315 subjects were 
excluded due to missing information on TE and TT, and 84 subjects with prevalent 
stroke, 85 women who used HT/did not have information on HT use and 26 women 
who were not postmenopausal, leaving  2,147 subjects, 1,124 men and 1,023 
women, for final analysis for the association of sex steroids and stroke incidence 
(Figure 1).  
Information on sex steroid measurement, carotid scanning and analysis of plaque 
components, stroke assessment and assessment of covariates can be found in 
Appendix 1. 
Statistical analyses  
Main Analysis 
Continuous variables are reported as mean ± standard deviation (SD) unless stated 
otherwise and categorical variables were presented as percentages. To achieve 
normal distribution, skewed variables (TT, SHBG, FAI, triglycerides, glucose, insulin, 
CRP, and TSH) were natural log transformed. All analyses were stratified by sex. 
Logistic regression models were used to evaluate whether sex steroids were 
associated with plaque composition. All sex hormones variables were assessed 
continuously (per SD increase) in separate models. As the minimum detection limit 
for TE was 18.35 pmol/liter, and 32.7 percent of women had values of TE lower than 
 CHAPTER 3.2 
96 
18.35, we analyzed TE as dichotomized variable (18.35 pmol/liter as reference 
category) in women. Therefore, in our analyses we compared women having 
undetectable TE levels (18.35 pmol/liter) being the reference group, versus women 
having detectable TE levels (>18.35 pmol/liter). Undetectable estradiol was not an 
issue in men since only 4 (0.48%) men participants had value of TE lower than the 
detection limit, and therefore we analyzed TE as continues variable (presented per 
1SD of estradiol increase). For men participants with estradiol levels lower than the 
detection limit, the value of 18,35 was assigned. In the sensitivity analysis, exclusion 
of men individuals with undetectable TE did not affect any of the investigated 
associations (data not shown) (16).  In the basic model (Model 1), we adjusted for 
age at baseline, time from hormone measurement at baseline and MRI scan (men: 
mean= 7.80 ±4.20 years and women: mean=7.43 ± SD=4.13 years), BMI, and sex 
steroids for each other. The main role of SHBG is the transport of sex steroids 
within the blood stream to extravascular target tissues. By binding testosterone and 
estradiol, SHBG regulates the balance between bioavailable testosterone and 
estrogens, and thus, might act as a confounder in the associations of TT and TE 
with plaque composition and risk of stroke. Also, upstream hormones, but not 
downstream hormones (which might act as mediators) in the cascade of sex 
hormone synthesis may act as confounders (Online figure I). Therefore, for TT we 
adjusted for SHBG, for TE we adjusted for SHBG and TT, for FAI we adjusted for E 
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and for SHBG we adjusted for TT and E). Model 2 was additionally adjusted for 
serum total cholesterol (continuous), statin use (yes vs. no), prevalent diabetes 
mellitus (presence versus absence), systolic blood pressure (continuous), 
antihypertensive medication (yes vs. no), prevalent cardiovascular disease at time of 
magnetic resonance imaging (yes vs no), smoking status (yes vs. no) and alcohol 
consumption (continuous). Cox proportional hazard modelling was used to 
evaluate whether TE and TT were associated with risk of stroke in subjects who 
were diagnosed with carotid atherosclerosis based on ultrasonography. Hazard 
ratios (HR) and 95% confidence intervals (95% CIs) were reported. We used same 
models as in the analysis for plaque composition as outcome. However, for these 
analyses, we corrected for age and prevalent cardiovascular disease (excluding 
stroke) at the time when sex steroid was measured.   
There were missing values on one or more covariates. Because the missing values 
were likely to be missing at random and for avoidance of loss in efficiency, missing 
values were imputed using a multiple imputation technique (5 imputation sets). 
Rubin’s method was used for the pooled coefficients (odds ratio (OR) or HR) and 
95% CIs (17). A P-value lower than 0.05 was considered as statistically significant, 
but to account for multiple testing, we adjusted the p-value from 0.05 to 0.025 by 
applying the Bonferroni correction for the number of exposures studied (N=2). All 
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analyses were done using SPSS statistical software (SPSS, version 21.0; SPSS Inc, 
Chicago, Illinois). 
Sensitivity Analysis 
We performed a series of sensitivity analyses using imputed data.  First, we 
repeated the analysis on sex hormones and plaque composition by using tertiles of 
endogenous sex hormone, and, to study the relations across increasing tertiles, 
trend tests were computed by entering the categorical variables as continuous 
variables in the logistic regression models. To account for the specific effects of 
lipid particles on carotid plaque composition and risk of stroke we substituted total 
cholesterol with HDL-C, TG, and LDL-C. We created additional models adjusting 
further for TSH (continuous), glucose and insulin (continuous), CRP (continuous), 
DHEA (continuous) and maximal carotid plaque thickness (continuous). Number of 
pregnancies, age of menarche and type of menopause (non-natural vs. natural) are 
associated with sex hormone levels, therefore, we built another model adjusting 
further for these factors in women. In both men and women, effect modifications of 
sex hormones by BMI, age and years since menopause (in women) were tested by 
adding an interaction term in the final multivariable model in addition to 
performing stratified analysis. Since there was a time difference between time of 
sex steroids measurements and MRI assessment, we stratified analysis by median 
time difference between the two assessments (men: median=9.91years, women: 
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9.00 years). Also, to account for effects of statin use on plaque composition, we 
further corrected for statin use frequency and duration, and in stratified analysis we 
excluded statin users. Also, we performed analysis excluding individuals with 
prevalent CVD at time of MRI scan. Additionally, we investigated whether SHBG and 
FAI were associated with plaque composition and risk of stroke. Also, we restricted 
the analysis on sex steroids and stroke to the participants who had also information 
on plaque composition (n=1498). Among these subjects we further investigated the 
effect of carotid plaque characteristics and risk of stroke. We created additional 
models adjusting for carotid plaque thickness and for plaque composition 
(presence of calcification, lipid core and intraplaque hemorrhage in individual 
models, as well as the three variables in the model). We also restricted our analysis 
on sex hormones and risk of stroke to subtypes of stroke (ischemic only, and 
ischemic and unspecified types of stroke). Finally, we performed the analysis on sex 
hormones and risk of stroke in women and men without atherosclerosis. 
Atherosclerosis has shown to lead to changes in expression of sex hormones 
receptors and thus, might modify the effect of sex hormones on risk of stroke (18). 
Further, the “timing hypothesis” indicates that estradiol might have adverse effects 
mainly in women with underlying atherosclerosis (18, 19). 
Results 
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Table 1 summarizes the baseline characteristics of the participants included in the 
main analysis (the association between sex steroids and carotid plaque 
composition). A total study population 1480, included 645 (43.58%) 
postmenopausal women and 835 (56.42%) men. The mean age of women was 
65.54 years (SD 7.22), and men 63.79 (SD 6.72). Women were on average 17.29 
years (SD 9.11) into menopause, and majority of the women (66.4%) experienced 
natural menopause. Calcified carotid plaques were present in 1220 (82.4%) 
participants, 532 women (82.5%) and 688 (82.4 %) men. Lipid core was detected in 
651 (43.9%) participants, 238 (36.9%) women, and 413 (49.46%) men. Intraplaque 
hemorrhage was observed in 521 (35.2 %) individuals, 187(29.0%) women and 
334(40.0 %) men. Selected characteristics of study participants for the analysis on 
sex steroids and risk of stroke were similar to the study population for plaque 
composition as outcome (Online Table I). As expected, considering that 36.9% of 
women and 25.7 % of men who did not perform MRI had contraindication or 
physical limitations, we found differences in age (women: mean age 68 vs. 65.5; 
men: 65.2 vs. 63.7) and incidence rate of stroke (women: 8.1/1000 person-years vs. 
4.8/1000 person years; men: 9.3/1000 person-years vs. 4/1000 person-years) 
among participants who did not attend and who attended MRI visit (Online table 
II). 
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Table 1. Characteristics of the Study Population 
 Women 
(n=645) 
Men 
(n=835) 
Age at baseline, mean (SD), y 65.54 (±7.22) 63.79 ±6.72 
Age at time of MRI scan, mean (SD), y 73.44 (±9.07) 71.60±9.10 
Carotid plaques   
Calcium plaques, yes  532 (82.5 %) 688 (82.4 %) 
Lipid plaques, yes  238 (36.9 %) 413 (49.5 %) 
Plaque hemorrhage, yes 187 (29.0 %) 334 (40.0 %) 
BMI, kg/m² 26.85(±4.10) 26.96 (±3.13) 
Smoking   
yes 153 (23.7%) 199 (23.8 %) 
no 487 (75.5%) 633 (75.8%) 
Alcohol intake g/day 8.40 (±13.39) 14.86 (±17.48) 
Health indicators    
Systolic BP, mmHg 139.13 (±20.47) 141.90 (±19.84) 
Antihypertensive therapy with indication, 
yes 
231 (35.8%) 303 (32.2%) 
Total cholesterol, mmol/l 6.0 (5.35-6.70) 5.63 (4.9-6.30) 
LDL, mmol/l 3.975 (±0.97) 7.70 (±1.55) 
HDL, mmol/l 1.51 (±0.39) 1.23 (±0.32) 
Triglycerides, mmol/l 1.36(1.02-1.81) 1.45 (1.08-2.00) 
Insulin, pmol/l 67.0 (48.0-98.0) 73.0 (51.0-107.0) 
Glucose, mmol/l 5.40 (5.1-5.9) 5.60 (5.20-6.20) 
CRP mg/l 1.70 (0.6-3.5) 1.40 (0.56-2.90) 
Serum lipid lowering medication, yes 148 (22.9%) 181 (21.7%) 
Prevalent diabetes mellitus 57 (8.8%) 117 (14.01%) 
Prevalent CVD at baseline 36 (5.6%) 89 (10.7%) 
Prevalent CVD at MRI 73 (11.3%) 166 (19.9%) 
Hormones   
Estradiol, pmol/l 32.06 (18.35-56.85) 100.10 (76.38-129.3) 
Testosterone, nmol/l 0.80 (0.60-1.08) 16.66 (13.09-20.88) 
SHBG, nmol/l 59.09 (42.14-79.99) 43.21 (33.87-55.31) 
DHEA, nmol/L 9.64 (6.26-14.13) 9.51 (6.31-13.99) 
FAI 1.32 (0.92-2.03) 38.72 (31.84-46.61) 
TSH mU/l 2.00 (1.28-3.17) 1.82 (1.27-2.60) 
Women-specific variables   
Age at menopause, years¹ 48.16 ±5.85 NA 
Years since menopause 17.29 (±9.11) NA 
Menopause type, natural menopause¹ 428 (66.4%) NA 
Age at menarche, years 13.56 (±1.69) NA 
Number of pregnancies 2 (1-3) NA 
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Values are reported as number (percentage) for categorical variables and means ±SD or 
median (25th–75th quartile) for continuous variables. Age at menopause, age at menarche, 
type of menopause and years since menopause were not available for all women, the 
present values are based on 631, 637, 638, and 631 women respectively. BMI indicates body 
mass index; BP, blood pressure; CRP, c-reactive protein; CVD, cardiovascular disease; FAI, free 
androgen index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MRI, magnetic 
resonance imaging; NA, not applicable; SHBG, sex hormone binding globulin; and TSH, 
thyroid-stimulating hormone. 
 
Sex steroids and Plaque Composition  
No associations were found between sex steroids and calcified carotid plaques in 
either sex (Table 2). After correcting for potential confounding factors, detectable 
TE levels in  women (TE levels > 18.35 comparing to  ≤18.35 pmol/l , odds ratio 
(OR) and 95% CI 1.48 [1.02, 2.15]) and higher TE levels in men per 1SD TE increase, 
OR and 95% CI 1.23 [1.03,1.46]) were associated with higher prevalence of lipid 
core in carotid plaques (Table 2). No associations were found between TT and 
presence of lipid core in either sex (Table 2). Detectable TE levels (TE levels > 18.35 
comparing to ≤18.35 pmol/l, OR and 95% CI 1.58 [1.03, 2.40]) and lower levels of TT 
(per 1SD TT increase OR and 95% CI 0.82 [0.68, 0.99] respectively) were also 
associated with higher prevalence of intraplaque hemorrhage in postmenopausal 
women irrespective of potential confounding factors. No association was found 
between TE, TT and intraplaque hemorrhage in men (per 1SD TE increase, OR and 
95% CI 0.94 [0.81, 1.09] and per 1SD TT increase OR and 95% CI 0.84 [0.69, 1.01]) 
(Table 2). 
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Model 1: Age, time difference between hormone measurement and MRI scan, body mass 
index (BMI), sex hormones for each other (for Estradiol we adjusted for SHBG and TT, for 
TT we adjusted for SHBG). Model2: Model 1+ total serum cholesterol (continuous), statin 
use (yes vs. no), prevalent diabetes mellitus (yes vs. no), systolic blood pressure 
(continuous), antihypertensive medication (yes vs. no), prevalent CVD at time of MRI, 
smoking status (yes vs. no) and alcohol consumption (continuous).† In women detectable 
TE levels (> 18.35 pmol/l) were compared to undetectable TE levels (≤18.35 pmol/l), in 
men results are presented per 1SD of estradiol increase. ‡Per 1SD increase of serum 
testosterone; *Results are presented as Odds ratio (OR) and 95% Confidence interval (CI 
95%); *Statistically significant results are bold (at level p<0.05); *Association remains 
significant at a Bonferroni corrected P < .025 for 2 tests. 
 
 
 
 
 
 
Table 2. Association between sex hormones and carotid plaque composition 
WOMEN 
(n=645) 
Calcified plaques 
OR (95% CI) 
Lipid Core, OR 
(95% CI) 
IPH 
OR (95% CI) 
Estradiol† 
Model 1 0.97 (0.77; 1.23) 1.40 (0.98; 2.00) 1.49 (1.01; 2.23) 
Model 2 1.06 (0.66; 1.71) 1.48 (1.02; 2.15) 1.58 (1.03; 2.40) 
Testosterone‡ 
Model 1 1.08 (0.96; 1.22) 0.99 (0.84; 1.17) 0.87 (0.73; 1.05) 
Model 2 1.03 (0.81; 1.31) 0.99 (0.84; 1.18) 0.82 (0.68; 0.99) 
MEN 
(n=835) 
Calcified plaques 
OR (95% CI) 
Lipid Core, OR 
(95% CI) 
IPH 
OR (95% CI) 
Estradiol†    
Model 1 0.94 (0.79;1.09) 1.22(1.06;1.39)* 0.95 (0.83;1.10) 
Model 2 0.94 (0.77;1.14) 1.23(1.03;1.46)* 0.94 (0.81;1.09) 
Testosterone‡    
Model 1 1.04 (0.93;1.17) 1.00 (0.84;1.19) 0.86 (0.71;1.02) 
Model 2 1.06 (0.84;1.34) 1.00 (0.84;1.19) 0.84 (0.69;1.01) 
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Association between sex steroids and risk of stroke  
During a median follow-up of 10.0 years, we identified 57 incident cases of stroke 
in women and 56 new cases of stroke in men. In the multivariable model (Model 2), 
women with detectable TE (TE levels > 18.35) as compared to women with 
undetectable TE ≤18.35 pmol/l had an increased risk of stroke in women (HR and 
95% CI 1.98 [1.01, 3.88]), whereas no association was found between TE and risk of 
stroke in men (Table 3). Also, no associations were found between TT and risk of 
stroke in either sexes (Table 3). 
Table 3. Association between sex steroids and risk of stroke 
 
WOMEN (n=1023) 
HR (95% CI) 
(57 stroke cases) 
P value MEN (n=1124) 
HR (95 % CI) 
(56 stroke cases) 
P value 
aEstradiol 
Model 1 
 
1.99 (1.42-2.79) 
 
0.04 
 
0.96 (0.83-1.11) 
 
0.77 
Model 2 1.98 (1.01-3.88) 0.04 0.98 (0.75-1.29) 0.91 
bTestosterone 
Model 1 
 
1.06 (0.93-1.21) 
 
0.67 
 
1.13 (0.78-1.66) 
 
0.52 
Model 2 1.04 (0.79-1.37) 0.77 1.10 (0.75 -1.62) 0.61 
Model 1: Age, body mass index (BMI), sex hormones for each other (for TT we adjusted for 
SHBG, for E we adjusted for SHBG and TT); Model 2: Model 1+ total serum cholesterol 
(continuous), statin use (yes vs. no), prevalent diabetes mellitus (yes vs. no), systolic blood 
pressure (continuous), antihypertensive medication (yes vs. no), prevalent CVD before the 
date of hormone measurement, smoking status (yes vs. no) and alcohol consumption 
(continuous); a in women detectable TE levels (> 18.35 pmol/l) were compared to 
undetectable TE levels (≤18.35 pmol/l), in men results are presented per 1SD of estradiol 
increase; b per 1SD testosterone increase; Results are presented as hazard ratio (HR) and 95% 
confidence interval (CI 95%); Statistically significant results are bolded; Analysis done in 
subjects diagnosed with carotid atherosclerosis using ultrasonography.  
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Sensitivity analysis  
Only the association between TE and lipid core presence in men remained 
significant after we applied the Bonferroni correction (p<0.025). In sensitivity 
analyses, using tertiles of sex hormones showed same results as the main analysis 
(Online figure Ia, Ib, Ic). Also, substituting total cholesterol for other blood lipids, 
adjusting further for number of pregnancies, age of menarche and type of 
menopause, statin frequency use, as well as for glucose, insulin, TSH, CRP, DHEA, 
maximal carotid plaque thickness and exclusion of individuals with prevalent CVD 
at the time of MRI scan did not materially affect any of the associations (Online 
table IIIa, IIIb and 4). Also, in the stratification analysis, no significant interactions 
were found for sex steroids with BMI, age, years since menopause or with carotid 
intima media thickness (Online table IIIa, IIIb and 4). Furthermore, the significant 
results we observed in the main analysis on sex steroids and plaque composition 
did not materially change when the analysis were restricted to participants with 
lower than the median (9 years) of the time difference in between sex steroids and 
MRI measurements. Also, the analyses stratified for time interval between sex 
hormones and MRI showed in general no differences in the results in either sex. 
Only for calcification and intraplaque hemorrhage, the effect estimate in women 
between estradiol and presence of calcification was larger in the stratum with short 
time interval compared with long time interval (Calcified plaques: OR, 1.70 (0.92-
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3.17) versus 0.36 (0.14-0.91), IPH (2.27 (1.15-4.48) versus 1.24 (0.69-2.20)) (Online 
table IIIa, IIIb). The results on sex steroids and plaque composition did not 
materially change when we further corrected for statin use frequency and duration 
(Online table IIIa, IIIb). After statin users were excluded from the analysis, the 
association between TE and lipid core presence and intraplaque hemorrhage was 
not anymore significant in women, but the magnitude of the effect did not 
materially change (Online table IIIa, IIIb). Also, no association was observed 
between SHBG and FAI with plaque composition and risk of stroke in either sex 
(Online table V, VI). The results on sex steroids and risk of stroke did not materially 
change when restricting the analysis to subjects with available data on plaque 
composition (Online table IV). In these subjects’ carotid plaque thickness and 
characteristics of carotid plaques did not affect the direction and magnitude of the 
association between TE and TT and risk of stroke (Online table VII). Exclusion of 
hemorrhagic stroke cases, and further of non-specified types, did not materially 
affect the associations of sex hormones with risk of stroke. (Online table IV).  
Restriction of the analysis on sex hormones and risk of stroke to participants 
without atherosclerosis diminished the association between TE and risk of stroke 
among women (Online table VIII).  
Discussion  
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In this population-based study among postmenopausal women and elderly men, 
we show sex differences in the association between estradiol, carotid plaque 
composition and risk of stroke. While TE was associated with higher prevalence of 
lipid core in both men and women, TE was associated with higher odds of having 
intraplaque hemorrhage and risk of stroke in women but not in men. No consistent 
association was observed between testosterone and plaque composition and risk 
of stroke in either sex (Illustration 1).  
Estradiol, plaque composition and risk of stroke  
Sex differences in the physiological actions of estradiol may underlie the sex 
differences we observed in our study, but another factor contributing can be the 
differences in sex hormone levels between men and women. In our sample, the 
distribution of estradiol and testosterone were different among men and women, 
with men having higher levels of both estradiol (median 100.10 pmol/L as 
compared to 32.06 pmol/L in women) and testosterone: median 16.66 nmol/l as 
compared to 0.80 in women nmol/l). Future studies with larger sample and wide 
distribution (range) of estradiol and testosterone levels in men and women are 
needed to understand further the role of sex hormones in atherosclerosis and risk 
of stroke. Our results on vulnerable plaque composition and increased risk of 
stroke with increasing levels of estradiol in women far from menopause (on 
average 17 years into menopause) are in line with the “timing hypothesis”, which 
 CHAPTER 3.2 
108 
theorizes that estradiol has harmful vascular effects in elderly women in contrast to 
neutral or beneficial effects in younger women (20, 21).  Also, in line with the 
“timing hypothesis”, the lack of association between total estradiol and risk of 
stroke in postmenopausal women without carotid atherosclerosis indicated that 
endogenous estradiol might have deleterious effects only in women with 
underlying atherosclerosis. Thus, the carotid atherosclerosis might act as an effect 
modifier on the association between TE and risk of stroke which needs to be 
addressed by future studies.  
Findings from animal studies based on monkey models in pre-menopause show 
estradiol to prevent fatty streak deposition and progression of atherosclerotic 
plaque (22). In contrast, in monkey models of female subjects 2 years into 
menopause (comparable to six postmenopausal years for women), no beneficial 
effect of estradiol was observed on the progression of coronary artery plaque (23). 
Similarly, studies among premenopausal women or in women in menopausal 
transition show that women using hormone therapy (HT) have a lower incidence of 
carotid atherosclerotic lesions (24), and slower progression of CIMT (25), while 
studies in postmenopausal women report no or deleterious effects (26, 27). Also, TE 
has beneficial effects in the vascular system in premenopausal women, whereas in 
postmenopausal women, large clinical trials have reported use of exogenous 
estradiol, which increases circulating estrogen levels, to increase risk of stroke (28, 
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29). Women’s Health Initiative (WHI) clinical trials reported harmful effect of HT on 
ischemic stroke risk in women older than 50 years of age (30, 31). Observational 
data from the Nurses’ Health Study confirmed those findings (32).  
Although, emerging evidence supports the “timing hypothesis”, the pathways still 
remain unclear.  It is early to say if switch from protective to harmful estradiol effect 
is due to changes in ER signaling (11) or it is a consequence of age-related hyper-
inflammatory state (33). Some experimental studies suggest molecular mechanisms 
that may contribute to hyper-inflammatory state and possibly promote pro-
inflammatory effect of estrogens in the aging vasculature (34). Also, the direct anti-
\atherogenic effect of estrogen are present, absent, or reversed, depending on the 
state of the arterial endothelium. Coronary artery fatty streaks and small plaques 
are common in women at the time of perimenopausal transition, while advanced 
atherosclerotic plaques are common in aging women and in women 5–15 years 
after menopause. Endothelium changes related to atherosclerosis progression in 
elderly women might be another explanation why hormone replacement therapy 
initiated at the complicated plaque stage (beyond about 60 years of age) can have 
either no beneficial effects or deleterious effects (23).  
In men, TE was associated with presence of lipid core, however, no association was 
observed with calcified carotid plaque, intraplaque hemorrhage or risk of stroke. 
Muller et al (35), demonstrated that higher E was associated with progression of 
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CIMT of the common carotid artery.  Study done in men with DM II showed inverse 
association between E and carotid atherosclerosis (36), while another study did not 
find any correlation between E and atherosclerosis in men (37). Evidences on 
association between E and risk of stroke in men are limited. In the Honolulu-Asia 
Aging Study, elevated serum E was cross-sectionally associated with  frequency of 
lacunar infarcts found on MRI (38). Study done in elderly men demonstrated 
positive correlation between E and stroke, however, they did not adjust for other 
sex hormones (39).  In line with our findings, two case-control studies did not find 
any correlation between E levels and stroke (40, 41).   
Total testosterone and plaque composition and risk of stroke  
In the present study, no association was observed between TT and FAI, plaque 
composition and risk of stroke in either sex.  
Animal models of atherosclerosis report contradictory results in both men and 
women. Few studies show that T has no effect (42) or beneficial effect on 
atherosclerosis in male animals (43), while in females exogenous androgen 
treatment may be atherogenic (44). Similarly, while cross-sectional studies in men 
and women have demonstrated inverse relation between T, CIMT and carotid 
plaque (45), longitudinal studies and clinical trials show no impact of T to CIMT 
progression, coronary artery calcification and plaque area (46). Limited and 
conflicting evidence exist also on T and stroke incidence. In a prospective 
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observational study of 3443 elderly men with a median follow-up of 3.5 years, men 
with low-normal T levels had increased risk of incident stroke and TIA combined 
(47). In contrast, T therapy use in cohort of veterans with significant medical 
comorbidities was associated with increased risk ischemic stroke (48). 
Strengths and limitations  
To the best of our knowledge, this is the first and most comprehensive study to 
examine the associations of estradiol and testosterone and carotid plaque 
composition in sample of postmenopausal women and men. Our sample was 
drawn from middle-aged and elderly subjects from the general population, which is 
one of the major strengths of our study. Total testosterone was measured using 
chromatography-tandem mass spectrometry, at the moment considered to be the 
gold standard method. High-resolution protocol-based MRI sequences are used to 
evaluate carotid plaque composition. Nevertheless, limitations of our study need to 
be discussed. First, a cross-sectional study design does not allow us to address the 
temporality of the observed associations, hence, we cannot draw any conclusions 
with regard to the causality of the observations. Second, in the RS there are no 
measures of bioavailable estradiol, which could have strengthened our results. Also, 
TE was measured using an immunoassay with a detection limit of 18.35 pmol/L, 
which is considered suboptimal particularly in postmenopausal women. Therefore, 
the analyses were done by categorizing the values into 0 if estradiol levels were 
 CHAPTER 3.2 
112 
≤18.35 pmol/l and 1 if the values were >18.35 pmol/l. Categorization of a 
continuous variable introduces loss of information and power. Third, we found 
difference between participants who attend MRI visit and who did not attend. 
However, majority of subjects who did not perform MRI had contraindication or 
physical limitations (38.73 %), therefore they might have been sicker comparing to 
the participants who were eligible to attend MRI. Also, it has been shown that using 
a selected source population for a cohort study usually leads to bias towards the 
null (49). Fourth, as our sample is population-based we chose not to administer 
gadolinium contrast to the participants, although lipid core is more easily detected 
with a contrast-enhanced MRI (50). However, in validation studies non-contrast-
enhanced MRI sequences have shown a good accuracy and reproducibility (51). 
Last, MRI assessment was measured only once and that measurement was taken 
after the exposure was measured, and therefore time difference between sex 
steroid measurements and MRI assessment exists. However, we did not find any 
difference in the results when main analysis was stratified by the time difference 
between the two assessments. Also, this study was carried out in middle-aged and 
elderly patients, and in older age hormone levels are more stable over time (52). 
Furthermore, the results on sex steroids and risk of stroke were on same direction 
as the results expected from sex steroids and plaque composition. Finally, the 
number of significant results on the association of TE, with plaque composition and 
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risk of stroke before correcting for multiple testing, but not after, as well as the 
presence of several methodological issues, suggests that our results are 
hypothesis-generating and should stimulate further studies on the possible 
influence of sex hormones on atherosclerosis and stroke risk. 
In summary, our findings suggest that endogenous estradiol may play a role in the 
development of vulnerable carotid plaque composition and increases risk of stroke 
in middle-aged elderly women. We hypothesize that endogenous estradiol levels in 
middle-aged elderly women can lead to plaque instability by increasing lipid 
content and intra-plaque hemorrhage which on the other hand can increase the 
risk of stroke.  The mechanisms by which estradiol levels can lead to adverse 
changes in plaque composition and subsequent risk for stroke in postmenopausal 
women remain largely unknown. Since the characteristics of carotid plaque did not 
alter the association between estradiol and risk of stroke, factors other than plaque 
composition parameters we evaluated can contribute to increased risk of stroke 
associated with high levels of estradiol in middle-aged and elderly women. Thus, 
further studies are needed to replicate our findings and to explore mechanisms of 
action of estradiol in carotid artery atherosclerosis, but also in other blood vessels. 
Additionally, our results encourage future research investigating whether estradiol 
might help to predict ischemic stroke in women with subclinical atherosclerosis, 
and thus, whether estradiol levels might be used in stroke risk prediction models. 
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Considering HT alters endogenous estradiol levels, our results raise a concern on 
whether the exogenous estradiol could have similar effect. Therefore, until future 
studies replicate or refute our findings, we believe HT should be taken with caution 
among women with similar characteristics to our study; postmenopausal women 
who already have diagnosis of carotid atherosclerosis and are further from 
menopause.   
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Abstract  
Background 
Statins represent a key treatment for cardiovascular disease. Nevertheless, the 
direct effects of statin treatment on the composition of atherosclerotic plaques 
remain elusive. 
Objectives 
We aimed to investigate the association of statin treatment with the presence of 
different plaque components located in the carotid arteries within a population-
based setting. 
Methods 
From the population-based Rotterdam Study, 1740 participants with carotid 
atherosclerosis (mean age 72.9 years, 46% women) underwent MRI of the carotid 
arteries to determine the presence of calcification, lipid core, and intraplaque 
hemorrhage. Information for the duration and dosage of statin use was obtained 
from pharmacy records for all participants. We used logistic regression models to 
study the association of statin use with the presence of plaque components. 
Results 
Statin treatment was associated with a higher presence of calcification (OR: 1.73 
[95%CI:1.22-2.44]). Longer duration of use strengthened this association (OR: 1.82 
[95%CI:1.00-3.33] for 10 to 48 months, and OR 1.74 [95%CI: 1.09-2.77] for > 48 
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months, compared to OR: 1.65 [95%CI:0.94-2.89] for ≤ 10 months). Current statin 
treatment was also associated with a lower presence of lipid core (OR: 0.66 
[95%CI:0.42-1.04]), but only when using statins for 10 months or less. Any dosage 
of statins was associated with a higher presence of calcification, whilst only high 
dosages (DDD > 1.33) were associated with a lower presence of lipid core. 
Conclusions 
Active, high-dosage statin use seems to beneficially influence the composition of 
carotid atherosclerosis by shifting the composition from vulnerable plaque with a 
lipid core to more stable calcified plaque. 
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INTRODUCTION 
Atherosclerosis in the carotid artery is the most important cause of stroke (1-3). 
Within the complex etiological framework of atherosclerosis, a key role is played by 
serum low-density lipoprotein (LDL) cholesterol, specifically in the initiation and 
progression of the disease (2). Following this, lowering the concentration of LDL 
cholesterol using statins has become a cornerstone for primary prevention of 
stroke and cardiovascular events overall (4, 5). 
Several trials have demonstrated a direct effect of statins on the formation of 
coronary artery disease and a lower risk of coronary events (6-8). This direct effect 
of statins is thought to be due to the beneficial influence of statins on plaque 
stability by increasing the amount of calcium at the cost of vulnerable plaque 
components such as lipid core (9). 
In contrast to the extensive research in the field of the coronary arteries, studies on 
the effects of statin treatment on atherosclerosis in the carotid arteries are far more 
limited, especially from a general-population perspective. Yet, especially in light of 
the increased risk of stroke that carotid atherosclerosis harbors (10), it is paramount 
to also disentangle the effect of statin treatment on carotid artery atherosclerosis. 
Moreover, it is important to highlight that findings regarding the physiopathology 
of coronary artery disease may not be directly generalizable to the carotid arteries, 
CHAPTER 4.1 
131 
given that correlation for atherosclerosis across vessel beds is only moderate (11, 
12). Magnetic resonance imaging (MRI) allows detailed characterization of different 
plaque components, including lipid core, intraplaque hemorrhage (IPH), and 
calcification (13, 14). 
Against this background, we investigated the association of statin use with specific 
components of the carotid plaque in a large population-based sample of persons 
with subclinical atherosclerosis. 
METHODS 
Setting 
The current study is embedded within The Rotterdam Study, a prospective 
population-based cohort study, in participants of ≥ 45 years living in Ommoord, a 
district of Rotterdam (15). The Rotterdam Study has been approved by the medical 
ethics committee, according to the Population Screening Act: Rotterdam Study, 
executed by the Ministry of Health, Welfare and Sports of the Netherlands. All 
participants provided written informed consent. 
Study population 
Participants were selected on the basis of a carotid artery ultrasound examination 
(intima-media thickness > 2.5 mm in one or both carotid arteries) which is 
performed in all participants of the Rotterdam Study. Between the year 2007 and 
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2012, 2666 participants were invited to undergo an MRI examination of the carotid 
arteries. From the invited participants, 684 participants did not undergo MRI 
scanning due to claustrophobia (n=57), physical limitations (n=191), MRI 
contraindications (n=115), refusal to participate (n=272) and no show or lost 
follow-up (n=49), leaving 1982 participants. From these, we excluded another 242 
participants due to poor image quality (n=95), scan interruption due to 
claustrophobia (n=106) and absence of plaque bilaterally (n=41), leaving 1740 
participants in the present analyses. 
2.3 Carotid scanning and analysis of plaque components 
MRI imaging was performed using a 1.5 Tesla scanner (GE Healthcare, Milwaukee, 
WI, USA) with a dedicated bilateral phase-array surface coil (Machnet, Eelde, the 
Netherlands). A standardized scanning protocol was used with a total scanning 
time of approximately 30 minutes. The protocol included 4 sequences in axial 
plane: a proton density weighted (PDw)-fast spin echo (FSE)-black blood (BB) 
sequence (in-plane resolution 130/160 x 130/128 = 0.8 x 1 cm); a PDw-FSE-BB with 
an increased in-plane resolution (in-plane resolution 130/224 x 130/160 = 0.5 x 0.8 
cm); a PDw-echo planar imaging (EPI) sequence (in-plane resolution 130/ 160 x 
70/160 = 0.8 x 0.4 cm); a T2 weighted-EPI sequence (in-plane resolution 130/160 x 
70/160 = 0.8 x 0.4 cm) and two three-dimensional (3D) sequences: a 3D-T1 
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weighted (T1w)-gradient echo sequence (in-plane resolution 180/192 x 180/180 = 
0.9 x 1 cm), and a 3D phased-contrast magnetic resonance angiography (3D-PC-
MRA) (in-plane resolution 180/256 x 180/128 = 0.7 x 1.4 cm). Details of the scan 
protocol, scan reading procedure, and reproducibility are described in detail 
elsewhere (16). We assessed plaque characteristics in all plaques with a maximum 
thickness of ≥2.5 mm on MRI. On the proton density weighted fast spin echo 
images, maximum carotid wall thickness was measured, and degree of luminal 
stenosis was calculated using the North American Symptomatic Carotid 
Endarterectomy Trial criteria (17). The carotid images were evaluated for the 
presence of three different plaque components, calcification, lipid core, and IPH. 
Calcification was defined as the presence of a hypointense region in the plaque on 
all sequences (18-20). IPH was defined as the presence of a hyperintense region in 
the atherosclerotic plaque on 3D-T1w-GRE (21, 22). Lipid core presence was 
defined as a hypointense region, not classified as IPH or calcification, in the plaque 
on PDw-FSE, PDw-EPI and T2w-EPI sequence, and with relative signal intensity drop 
on the T2w-EPI sequence (18, 19, 23). All sequences were used in parallel to record 
the presence of plaque components. Subjects were recorded as positive for the 
presence of any plaque component if the component was identified in one or both 
carotid arteries. To test the intra-subject variability, 40 participants underwent a 
second MRI scan (average time between scans 15±9 days) (16). For an inter-
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observer reproducibility analysis, MRI examinations were selected randomly (n=50) 
and read by a second independent observer with three years of experience. Inter-
observer agreement and intra-scan agreement were calculated using Cohens’ 
Kappa statistics. The intra-subjects agreement was good for all measurements. The 
Kappa values were 0·95 (95% CI 0·88-0·99) for the presence of intraplaque 
hemorrhage; 0·85 (95% CI 0·74-0·96) for lipid core and 0·91 (95% CI 0·82-0·99) for 
calcification (16). Moreover, interobserver agreement was good for all 
measurements. The Kappa values were 0·86 (95% CI 0·72-0·99) for intraplaque 
hemorrhage; 0·86 (95% CI 0·72-0·99) for lipid core presence and 0·94 (95% CI 0·86-
0·99) for calcification (16) 
Assessment of statin treatment 
Information on statin treatment dispensing was obtained from fully computerized 
linked pharmacies in the study area. All prescriptions for statin therapy filed from 
January 1, 1991, until October 26, 2012, were available and included the product 
name of the drug, the anatomical therapeutic chemical code (ATC code), the 
amount dispensed, the prescribed dose regimen, and the date of dispensing. For 
every dispensing of statins, the duration of use (prescription episode) was 
calculated by dividing the number of dispensed tablets by the prescribed daily 
number. On the date of carotid MRI scanning, every participant was classified into 
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one of the following mutually exclusive categories: ‘current use’ if the measurement 
occurred within a prescription episode; ‘past use’ if the participant had previously 
stopped using statins; or ‘never use’ if the participant had not used statins during 
the study period. Next, we created tertiles of the duration of cumulative exposure 
to statins among statin users. This resulted in the following categories: current use 
≤10 months; current use 10 - 48 months, current use >48 months and past use ≤10 
months; past use 10 – 48 months, past use >48 months since the end of the last 
prescription episode. To facilitate direct dose comparisons between drugs from the 
same therapeutic drug group, the daily defined dose (DDD) of statin therapy was 
expressed (24). Finally, we created tertiles of discontinuation of statin use among 
past users as follows:  ≤3 months, 3-16 months and >16 months. 
Other measurements in the Rotterdam Study 
Information on other relevant measurements was obtained by interview, physical 
examination, and blood sampling (15). Smoking status was categorized into never, 
the past, and current smoking. Diabetes mellitus was defined as fasting blood 
glucose >6.9 mmol/L, nonfasting glucose >11.0 mmol/L, or use of glucose-
lowering medication. Systolic and diastolic blood pressure was measured using a 
random-zero sphygmomanometer on the right arm. Two measurements were 
performed and the average of the two was used in the analyses. Body mass index 
(BMI) was calculated based on weight in kilograms divided by height in meters 
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squared. Serum total cholesterol and high-density lipoprotein (HDL) levels were 
measured using standard laboratory techniques. The use of antihypertensive 
medication and vitamin K antagonists (VKA) was obtained from pharmacy records 
(15). 
Statistical analysis 
We used a three-step statistical analysis approach to investigate the association 
between statin use and the presence of different plaque components. First, we used 
two logistic regression models to assess the association of statin use (never, former, 
current) with the presence of calcification, lipid core, and IPH in any of the two 
carotid arteries. In the first model, we adjusted these analyses for age and sex. In 
the second model, we additionally adjusted for smoking, diabetes mellitus, systolic 
blood pressure, diastolic blood pressure, BMI, total cholesterol, HDL, use of 
antihypertensive medication, and use of vitamin K antagonists. Factors were 
selected based on previous literature and univariate analyses. Vitamin K antagonists 
were handled as a potential confounder given that these accelerate the deposition 
of calcification in the arterial wall through the competitive lowering of vitamin K 
receptor binding. Second, we investigated whether the duration of statin use was 
associated with any of the three plaque components, using the same regression 
models. For the duration of statin use, we compared the six categories as defined 
above (based on tertiles of use), vs. never use. Third, we investigated whether the 
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DDD of statin treatment was associated with any of the three plaque components. 
Fourth, we created tertiles of DDD of statin treatment and compared the three 
tertile categories with never use. Finally, we investigated the association of 
discontinuation of statin use with plaque composition (based on tertiles of 
discontinuation). 
Additionally, we performed sensitivity analyses to address confounding by 
indication, we re-analyzed all associations in participants without prevalent 
cardiovascular diseases (participants with a confirmed history of stroke, myocardial 
infarction, and coronary heart disease) (Table 1) (4, 5). Finally, we performed 
stratified analyses for age below and above 70 years of age and sex, to investigate 
whether associations differed by these factors. All analyses were carried out using 
IBM SPSS Statistical package version 21 (Chicago, IL, USA). 
RESULTS 
Table 1 presents the baseline characteristics of the study population. Among study 
subjects a total of 30.2% on statin treatment at the time of MRI. In statin users, the 
median duration of exposure to statins was 48 months (interquartile range, 10 – 
110 months) with varying DDD regimes. Whereas in the statin past users the 
median statin discontinuation was 16 months (interquartile range, 3 – 48 months).  
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Table 1 Baseline characteristics of the study population (n=1740) 
 
Never user 
N=1014 
Current 
user 
N=526 
Past user 
N = 200 
Age (years) 72.05±9.9 73.60±8.0 75.44±6.8 
Women (%) 48.8 38.2 52.0 
Current smoking (%) 30.8 33.5 30.0 
Diabetes mellitus (%) 8.2 24.0 21.0 
Systolic blood pressure (mm/Hg) 144.6±20 146.1±21 148.4±20 
Diastolic blood pressure (mm/Hg) 80.7±10 79.2±10 80.1±12 
BMI (kg/m2) 27.0±3.6 27.6±3.2 27.9±3.7 
Total cholesterol (mmol/L) 5.83±0.8 5.22±1.1 5.65±1.1 
HDL cholesterol (mmol/L) 1.46±0.3 1.29±0.3 1.37±0.3 
Antihypertensive medication use (%) 27.4 59.1 47.5 
Vitamin K antagonists use (%) 4.2 8.4 5.0 
History of stroke (%) 2.5 12.0 10.5 
History of myocardial infarction (%) 1.9 21.5 20.0 
History of CHD (%) 1.4 26.8 22.0 
Degree of stenosis (%) mean±SD 16.1±17.5 22.3±23.3 20.4±21.4 
Wall thickness, mm 3.1±0.6 3.3±0.7 3.3±0.8 
Presence of calcification 78.7 88.4 84.5 
Presence of lipid core 45.0 42.4 43.5 
Presence of IPH 30.7 39.5 42.0 
Values are means with standard deviations for continuous variables and percentages for 
dichotomous or categorical variables. Abbreviations: BMI = body mass index, CHD = 
coronary heart disease, HDL = High-density lipoprotein 
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Statin use and plaque composition 
Current statin use was associated with the presence of calcification and lipid core 
(age, sex and carotid wall thickness adjusted odds ratios [OR]: 1.77, and 0.78, 
respectively). After additional adjustment for cardiovascular risk factors, only the 
association between current statin use and the presence of calcification remained 
statistically significant (OR: 1.73 [95%CI: 1.22-2.44]) (Table 2). We found no 
association between current statin use and the presence of IPH. Moreover, we 
found no association of past statin use with any of the plaque characteristics. 
Table 2 Association between statin treatment and carotid artery plaque 
composition 
Duration of statin use and plaque composition 
Longer duration of statin use was associated with a higher presence of calcification 
(for statin use of 10 months OR: 1.65 [95%CI:0.94-2.89]), (for statin use of 10 to 48 
Statin use 
Calcification 
OR (95%CI) 
Lipid core 
OR (95% CI) 
IPH 
OR (95% CI) 
Never use Ref Ref Ref 
Current use 1.73 (1.22-2.44) 0.91 (0.72-1.16) 1.07 (0.82-1.40) 
Past use 1.13 (0.73-1.75) 0.99 (0.71-1.37) 1.35 (0.94-1.92) 
Global P-value over 
statin use categories 
<0.05 >0.05 <0.05 
All estimates were adjusted for age, sex, carotid wall thickness, smoking, diabetes mellitus, 
systolic blood pressure, diastolic blood pressure, body mass index, total cholesterol, high-
density lipoprotein, blood pressure-lowering medication use and vitamin K antagonists use. 
Abbreviations: CI = confidence interval, IPH = intra-plaque hemorrhage, OR = odds ratio. 
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months OR: 1.82 [95% CI: 1.00-3.33]), and (for statin use of more than 48 months 
OR: 1.74 [95% CI: 1.09-2.77]) (p-trend 0.01) (Table 3). We also found an association 
between the current statin use of ≤10 months with a lower presence of lipid core 
(OR: 0.54 [95% CI: 0.35-0.83]). After additional adjustment this association was not 
significant (OR: 0.66 [95% CI: 0.42-1.04]). We found no associations for any length 
of past use with any of the plaque components (Table 3). 
Table 3 Association between duration of statin treatment and plaque composition 
Statin use 
Calcification 
OR (95%CI) 
Lipid core 
OR (95% CI) 
IPH 
OR (95% CI) 
Never use Ref Ref Ref 
Current ≤ 10 months 1.65 (0.94-2.89) 0.66 (0.42-1.04) 1.25 (0.76-2.04) 
Current 10–48 months 1.82 (1.00-3.33) 0.95 (0.64-1.40) 0.81 (0.52-1.27) 
Current > 48 months  1.74 (1.09-2.77) 1.00 (0.74-1.34) 1.14 (0.83-1.58) 
Past ≤ 10 months 0.82 (0.44-1.52) 1.04 (0.63-1.71) 1.89 (1.11-3.22) 
Past 10 – 48 months 1.50 (0.65-3.45) 1.28 (0.72-2.25) 1.79 (0.97-3.29) 
Past > 48 months 1.37 (0.65-2.90) 0.76 (0.45-1.29) 0.71 (0.39-1.30) 
Global P-value over 
statin use categories 
< 0.05 > 0.05 < 0.05 
All estimates were adjusted for age, sex, carotid wall thickness, smoking, diabetes mellitus, 
systolic blood pressure, diastolic blood pressure, body mass index, total cholesterol, high-
density lipoprotein, blood pressure-lowering medication use and vitamin K antagonists use. 
Abbreviations: CI = confidence interval, IPH = intra-plaque hemorrhage, OR = odds ratio. 
Dosage of statin use and plaque composition 
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Figure 1. Association of statin treatment, according to defined daily dosage (DDD) on 
carotid composition. In all three sections are represented the association of the 
calcification, lipid core, and intraplaque hemorrhage. Values on the y-axis represent the 
odds ratios per DDD tertiles. The values are adjusted for age, sex, carotid wall thickness, 
smoking, diabetes mellitus, systolic blood pressure, diastolic blood pressure, body mass 
index, total cholesterol, high-density lipoprotein, antihypertensive medication use, and 
vitamin K antagonists use. 
 
We found a dose-response relation between the DDD of statin use and a higher 
presence of calcification and a lower presence of lipid core (Figure 1). The high 
statin dosage did not associate with a presence of IPH, even after adjustment for 
cardiovascular risk factors (Figure 1). 
Discontinuation of statin use and plaque composition 
When we examined associations between the discontinuation of statin use in past 
users, we found a positive trend of ≤3 months of statin discontinuation with a 
higher presence of calcification (OR: 1.48 [95% CI: 0.60-3.61]) and the positive trend 
CHAPTER 4.1 
142 
of statin discontinuation of more than >16 months with a lipid core. Interestingly, 
we also found that discontinuation of longer than 3 months (i.e. 3-16 months) was 
associated with a higher presence of IPH (OR: 1.66 [95% CI: 1.05-2.64]) 
(Supplementary Table 1). 
Sensitivity and stratified analyses  
After excluding participants with a history of CVD, the results did not substantially 
change (Supplementary Table 2). When we compared the association of statin use 
with the presence of calcification among persons younger than ≤70 vs. those older 
than >70, we found that current use and past use was associated most prominently 
with the presence of calcification and IPH in persons younger than ≤70 
(Supplementary Table 3). We found no differences between men and women 
(Supplementary Table 4). 
DISCUSSION 
In this large sample of middle-aged and elderly community-dwelling individuals, 
we observed that current use of a statin is related to a higher presence of 
calcification and a lower presence of lipid core in the carotid atherosclerotic plaque. 
A longer duration of statin use was primarily associated with the presence of 
calcification. Moreover, higher dosages of statins were related to a higher presence 
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of calcification and a lower presence of lipid core. We found no influence of past 
statin use on carotid plaque components. 
The current findings suggest that statins may play an important role in the 
remodeling of the atherosclerotic plaque composition and potentially change the 
natural course of atherosclerotic disease in the carotid artery. Thus far, evidence on 
the role of statins comes from several clinical studies investigating the effect of 
statins on cardiovascular disease (6-8), mainly targeting coronary arteries and the 
risk of coronary heart disease (25-27). Primarily, these studies consistently 
demonstrated that plaques tend to regress (i.e. Diminish in size) under the 
influence of statins and statins plays a role in risk reduction of atherosclerotic 
cardiovascular events (28-32). However, evidence from trials with patients, 
targeting carotid artery, demonstrated that statin treatment markedly reduced 
intima-media thickness, plaque volume, lipid core and increased calcification (28, 
33-35). Collectively, these studies examined the effect of statins and attributed the 
beneficial role of statins based on their ability to reduce cardiovascular events but 
did not elucidate the direct effect of statins on plaque composition. Our study 
differed from these prior investigations, particularly as we investigated in detail the 
plaque components of atherosclerotic plaques. In this context, our findings indicate 
that statins inhibit progression of vulnerable components (i.e. lipid core in the 
atherosclerotic plaque), promotes calcification of the plaque and here with the 
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transition from vulnerable to the stable plaque. Similar findings have been reported 
by a Multicenter CONFIRM study, which investigated the effects of statins on 
coronary plaque composition (36). In support of our findings a similar trend with 
calcification, lipid core, and intraplaque hemorrhage has been reported by the 
study, within Rotterdam study, when assessed the effect of statins on the incidence 
or the persistence of calcification, lipid core and IPH after 4 years of follow-up in 
longitudinal design, but owing to a small study sample limited the capacity to 
detect associations (37). Although our study design was cross-sectional, we may 
hypothesize that statins remodel the atherosclerotic plaque composition, thereby, 
accelerate calcification of the plaque under statin treatment whilst at the same 
time, decrease lipid core. However, pathological observations suggest the central 
role of the vascular smooth muscle cells and macrophage apoptosis as driving 
mechanisms of calcification (38). Aside from lipid regression within a plaque statin 
treatment may promote calcification in the plaque, herein plaque stabilization (25). 
Similarly, recent PET studies related effects of statins with reduced vascular 
inflammation and vascular calcification (39, 40). Therefore, it is likely that the 
beneficial role of statins may be attributed to the capacity of statins to remodel the 
composition of the atherosclerotic plaque towards more calcification and less non-
calcified components. Importantly, the amount of calcification as a measure of 
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plaque-stability and a potential indicator of lower risk of subsequent clinical events 
requires further research (41).  
Statin treatment produces observable changes in the plaque after short periods of 
use, nevertheless, it remains unclear to what extent of the duration of use statins 
can alter plaque morphology into a stable plaque phenotype. In the current study, 
we were able to consider the three different cutoffs for the duration of use and 
dosage. These findings suggest that statins are capable of promoting calcification 
in the short term of use, in low and high dosages, whereas the regression of lipid 
core can be achieved only through high dosages (42). Alternatively, weighing the p-
trends we may hypothesize that duration of use significantly relates to calcification 
component and dosage of use relates to lipid component. At this point, an 
important clinical finding has been reported from a middle-aged patient who 
presented with moderate ischemia and coronary computed tomography (CTA) 
revealed a large amount of atherosclerotic plaque in the proximal left circumflex 
coronary artery. Among the others, the patient has been put in statin high dosage 
treatment (43). After 4 years the same patient returned back, the coronary CTA was 
performed, and it showed a marked reduction of plaque amount (43). Similarly, our 
findings may suggest that a longer duration and high dosages of statin treatment 
should be considered to lower the risk of atherosclerotic CVD on primary 
prevention (44-46). Furthermore, we highlight that duration and daily dosage of 
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statin treatment are key factors to determine the direction of plaque remodeling 
process and plaque morphology.  
In contrast to our findings with current statin use, we did not find evidence for 
beneficial effects of past statin use suggesting a narrower window of exposure to 
treatment in order to accrue these effects.  This is underlined by our finding that 
discontinuation of 3 months or longer was associated with a higher presence of 
vulnerable components, namely lipid core, and intraplaque hemorrhage. This may 
thus indicate that cessation of statin treatment will eventually lead to the 
continuation of plaque development, which could be comparable to the 
development prior to statin use. These findings are in line with a recent study in 
which the discontinuation of statin use led to an increased risk of myocardial 
infarction and cardiovascular mortality (47). Following this, future longitudinal 
studies that take into account the effect of statin use on clinical outcomes such as 
cardiovascular events and mortality, are warranted.  
The major strength is that our study is the first population-based study, with a long 
duration of exposure to statins, to investigate the association of statin use with 
carotid plaque components in a relatively large study sample. All data were 
collected irrespective of the current study. Furthermore, we were able to 
characterize in detail each specific component of the carotid atherosclerotic plaque 
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using MRI. Additionally, we were able to take into consideration the duration and 
dosing of statin therapy. Yet, some considerations with regard to our study should 
also be addressed. First, although we conducted a sensitivity analysis confounding 
by indication in participants with a history of CVD should be considered. Second, 
due to the observational nature of the study, our findings should be regarded as 
hypothesis-generating and non-conclusive. Third, we were not able to consider the 
quantitative measures of each component within the atherosclerotic plaque. The 
quantitative assessments may provide additional, unique information on plaque 
composition and that future endeavors will also involve quantitative plaque 
assessments. Fourth, the potential of the MRI or CT versus PET/CT on detection of 
microcalcification is weak (48), therefore the interpretation of our results on 
calcification should be in the context of the macrocalcification.   
Conclusions 
In summary, we found that current statin treatment and high dosages of statins 
seem to beneficially influence the composition of the atherosclerotic plaque in the 
carotids by lowering the presence of the vulnerable lipid core component and 
contributing to a higher presence of stable calcified plaques.                                                                                             
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Supplementary Table 1 Association between discontinuation of statin treatment 
and carotid artery plaque composition 
Statin use 
Calcification 
OR (95%CI) 
Lipid core 
OR (95% CI) 
IPH  
OR (95% CI) 
Never use Ref Ref Ref  
D ≤3 months 1.48 (0.60-3.61) 0.93 (0.51-1.69) 0.72 (0.35-1.47) 
D 3-16 months 0.88 (0.50-1.56) 0.84 (0.54-1.31) 1.66 (1.05-2.64) 
D > 16 months 0.77 (0.35-1.71) 1.56 (0.86-2.81) 1.37 (0.72-2.59) 
All estimates were adjusted for age, sex, carotid wall thickness, smoking, diabetes mellitus, 
systolic blood pressure, diastolic blood pressure, body mass index, total cholesterol, high-
density lipoprotein, blood pressure-lowering medication use and vitamin K antagonists use. 
Abbreviations: CI = confidence interval, D = Statin discontinuation, IPH = intra-plaque 
hemorrhage, OR = odds ratio. 
 
Supplementary Table 2 Association of statin treatment on carotid plaque 
composition in individuals free of stroke, MI, and coronary heart disease 
Statin use 
Calcification 
OR (95%CI) 
 
Lipid core 
OR (95% CI) 
 
IPH 
OR (95% CI) 
 
Never use Ref  Ref  Ref  
Current use 2.12 (1.37-3.28)  0.92 (0.69-1.24)  1.26 (0.91-1.75)  
Past use 1.09 (0.65-1.83)  0.90 (0.60-1.35)  1.41 (0.91-2.18)  
All estimates were adjusted for age, sex, carotid wall thickness, smoking, diabetes mellitus, 
systolic blood pressure, diastolic blood pressure, body mass index, total cholesterol, high-
density lipoprotein, blood pressure-lowering medication use and vitamin K antagonists use. 
Abbreviations: CI = confidence interval, D = Statin discontinuation, IPH = intra-plaque 
hemorrhage, OR = odds ratio. 
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Supplementary Table 3 Association of statin treatment with carotid plaque 
components, stratified by age 
Statin use 
Calcification 
OR (95%CI) 
 
Lipid core 
OR (95% CI) 
 
IPH 
OR (95% CI) 
≤70 years                                                              
Never use Ref  Ref  Ref  
Current 
use 
2.57 (1.51-4.36)  1.14 (0.75-1.75)  1.46 (0.89-2.41)  
Past use 3.77 (1.26-11.31)  1.03 (0.49-2.15)  2.73 (1.25-5.96)  
>70 years                                                               
Never use Ref  Ref  Ref  
Current 
use 
1.29 (0.81-2.04)  0.81 (0.60-1.09)  0.91 (0.66-1.26)  
Past use 0.78 (0.47-1.28)  0.97 (0.67-1.42)  1.10 (0.73-1.64) 
All estimates were adjusted for age, sex, carotid wall thickness, smoking, diabetes mellitus, 
systolic blood pressure, diastolic blood pressure, body mass index, total cholesterol, high-
density lipoprotein, blood pressure-lowering medication use and vitamin K antagonists use. 
Abbreviations: CI = confidence interval, D = Statin discontinuation, IPH = intra-plaque 
hemorrhage, OR = odds ratio. 
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Supplementary Table 4 Association of statin treatment with carotid plaque 
components, stratified by sex 
Statin use 
Calcification 
OR (95%CI) 
 
Lipid core 
OR (95% CI) 
 
IPH 
OR (95% 
CI) 
 
Male                                                                      
Never use Ref  Ref  Ref  
Current use 1.66 (1.06-2.61)  0.91 (0.66-1.24)  1.02 (0.72-1.44)  
Past use 1.11 (0.59-2.08)  1.14 (0.71-1.82)  1.53 (0.92-2.53)  
Female                                                                 
Never use Ref  Ref  Ref  
Current use 1.88 (1.09-3.26)  0.95 (0.64-1.40)  1.21 (0.79-1.86) 
Past use 1.18 (0.64-2.20)  0.91 (0.57-1.45)  1.20 (0.72-2.00) 
All estimates were adjusted for age, sex, carotid wall thickness, smoking, diabetes mellitus, 
systolic blood pressure, diastolic blood pressure, body mass index, total cholesterol, high-
density lipoprotein, blood pressure-lowering medication use and vitamin K antagonists use. 
Abbreviations: CI = confidence interval, D = Statin discontinuation, IPH = intra-plaque 
hemorrhage, OR = odds ratio. 
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ABSTRACT AND KEYWORDS 
Aim 
Antithrombotic treatment plays a key role in stroke prevention, but their direct 
effects on the composition of carotid artery atherosclerotic plaques are unknown. To 
investigate the association of antithrombotic treatment with carotid artery plaque 
composition, with a specific focus on an intraplaque hemorrhage.  
Methods 
From the population-based Rotterdam Study, 1740 participants with carotid 
atherosclerosis on ultrasound (mean age 72.9 years, 46.0 women) underwent MRI of 
the carotid arteries to assess plaque composition. Information on the use of oral 
anticoagulants (vitamin K antagonists) and antiplatelet agents (salicylates), including 
duration of use and dosage, was obtained from pharmacy records for all participants. 
We used logistic regression models to assess the association between the use of 
anticoagulants and antiplatelet agents, and the different plaque components 
adjusting for confounders. 
Results 
Current and past use of vitamin K antagonists (adjusted odds ratio (OR): 1.88 [95% 
confidence interval (CI): 0.74-4.75], and OR 1.89 [95%CI: 0.91-3.93]) and antiplatelet 
agents (OR: 1.22 [95%CI: 0.91-1.62]), and OR: 1.23 [95%CI: 0.86-1.75]) showed 
positive trend with a higher presence of intraplaque hemorrhage. Also, a longer 
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duration of use was associated with a higher frequency of intraplaque hemorrhage 
(OR: 3.15 [95%CI: 1.23-8.05]) for the use of vitamin K antagonists, and longer duration 
of the use for antiplatelet agents showed a positive trend (OR: 1.21 [95%CI: 0.88-
1.67]). We also found that higher levels of INR above 2.97 for vitamin K antagonists 
(OR: 1.48 [95%CI: 1.03-2.15]) and higher daily defined dosage than 1.0 for antiplatelet 
agents (OR: 1.50 [95%CI: 1.21-1.87]) were related to a higher frequency of intraplaque 
hemorrhage. We found no association with lipid core or calcification. 
Conclusions 
The use of antithrombotic treatment relates to a higher frequency of intraplaque 
hemorrhage in carotid atherosclerotic plaques.  
 
ABBREVIATIONS: 
DDD = daily defined dosage,  
INR = international normalized ratio,  
IPH = intraplaque hemorrhage,  
MRI = magnetic resonance imaging,  
PDw-FSE = proton density fast spin echo image,  
PDw-EPI = proton density echo planar image,  
T2w-EPI = T2 weighted echo planar image,  
3D-T1w-GRE = 3D T1 weighted gradient echo sequence. 
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INTRODUCTION 
Atherosclerotic disease in the carotid artery is considered a key risk factor for 
ischemic stroke. In recent years considerable efforts have been put in the 
development of strategies to prevent the occurrence of both new and recurrent 
ischemic strokes (1-5). An important cornerstone of these strategies is the 
prescription of oral anticoagulants and antiplatelet agents, given their beneficial 
effect on lowering the risk of cardiovascular events, including strokes (6). Despite this 
benefit of oral anticoagulants and antiplatelet agents (7), their effects on the 
development or changes in already existing atherosclerotic carotid plaque are 
unknown (8). Emerging technological development in magnetic resonance imaging 
(MRI) enables a detailed characterization of carotid plaque components like 
intraplaque hemorrhage (IPH), lipid core and calcification (8-10), which play an 
important role in future thromboembolic events (11-14). Recently, in a relatively 
small sample of symptomatic patients, it was highlighted that antithrombotic 
treatment may exert a potentially harmful effect on the composition of carotid 
atherosclerotic plaques (8). Specifically, the use of antiplatelet agents was related to 
a higher presence of intraplaque hemorrhage, which is a plaque component that is 
known to be more prevalent in plaques that are prone to rupture (8). However, 
several important questions on this topic remain as previous studies were in 
symptomatic patients with advanced atherosclerosis. First, the influence of using 
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vitamin K antagonists (VKA), which is also frequently prescribed for prevention of 
cardiovascular events of cardiac origin like as atrial fibrillation, on the composition 
of carotid atherosclerosis remains unclear. Second, the duration and dosage of use 
of vitamin K antagonists or antiplatelet agents may substantially affect the carotid 
plaque composition but has not been studied before. Therefore, we investigated in 
a large sample of subjects with subclinical atherosclerosis from the Rotterdam Study, 
the associations between oral antithrombotic treatment and carotid plaque 
composition, with a special focus on intraplaque hemorrhage.  
METHODS 
Study population 
This study is embedded within a prospective population-based cohort, The 
Rotterdam Study (15). Between the year 2007 and 2012 participants with carotid 
atherosclerosis were invited to undergo an MRI scan of the carotid arteries. 
Previously, participants were selected on the basis of a carotid artery ultrasound 
examination (intima-media thickness ≥ 2.5 mm in one or both carotid arteries) 
performed in all participants of the Rotterdam Study. From the 2666 invited 
participants, 684 did not undergo MRI scan, and 1982 did (74%). From them, 242 
participants were excluded and 1740 were included in the present study (Figure 1). 
The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC and by the Dutch Ministry of Health, Welfare and Sports, implementing 
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the “Wet Bevolkings Onderzoek: ERGO (Population Screening Act: Rotterdam 
Study)”. All participants provided written informed consent to participate in the study 
and to obtain information from their treating physicians. 
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Carotid scanning and analysis of plaque components 
A 1.5 Tesla scanner (GE Healthcare, Milwaukee, WI, USA) with a dedicated bilateral 
phase-array surface coil (Machnet, Eelde, the Netherlands) was used to perform 
bilateral imaging of the carotid artery, with a standardized scanning protocol, which 
required an approximate total scanning time of 30 minutes. The protocol included 
four sequences in axial plane: a proton density weighted (PDw)-fast spin echo (FSE)-
black blood (BB) sequence (in-plane resolution 130/160 x 130/128 = 0.8 x 1 cm); a 
PDw-FSE-BB with an increased in-plane resolution (in-plane resolution 130/224 x 
130/160 = 0.5 x 0.8 cm); a PDw-echo planar imaging (EPI) sequence (in-plane 
resolution 130/ 160 x 70/160 = 0.8 x 0.4 cm); a T2 weighted-EPI sequence (in-plane 
resolution 130/160 x 70/160 = 0.8 x 0.4 cm) and two three-dimensional (3D) 
sequences: a 3D-T1 weighted (T1w)-gradient echo sequence (in-plane resolution 
180/192 x 180/180 = 0.9 x 1 cm), and a 3D phased-contrast magnetic resonance 
angiography (3D-PC-MRA) (in-plane resolution 180/256 x 180/128 = 0.7 x 1.4 cm) 
(16). More details of the scanning protocol, reading procedure, and reproducibility 
are described in detail elsewhere (17). The images of the carotid were evaluated for 
the presence of three different plaque components: Intraplaque hemorrhage, lipid 
core, and calcification. Calcification was defined as the presence of a hypointense 
region in the plaque on all sequences (16, 18, 19). Intraplaque hemorrhage was 
defined as the presence of a hyperintense region in the atherosclerotic plaque on 
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3D-T1w-GRE (20, 21). Lipid core presence was defined as a hypointense region, not 
classified as intraplaque hemorrhage or calcification, in the plaque on PDw-FSE or 
PDw-EPI and T2w-EPI images or a region of relative signal intensity drop in the T2w-
EPI images compared with the PDw-EPI images (18, 19, 22). Two independent MRI 
readers, with 3 years of experience, not being aware of any of the clinical 
characteristics of the participants, including the medication recorded subjects as 
positive for the presence of any plaque component if the component was identified 
in one or both carotid arteries. Testing the intra-subject variability, 40 participants 
underwent a second MRI scan (average time between scans 15±9 days) (17).  For an 
interobserver reproducibility analysis, MRI examinations were selected randomly 
(n=50) and read by a second independent observer with three years of experience. 
Further, using Cohens’ Kappa statistics interobserver and an intra-scan agreement 
was calculated. The intrasubject agreement was good for all measurements. The 
Kappa value for the presence of intraplaque hemorrhage was 0.95 (95% CI 0.88 – 
0.99); for lipid core was 0.85 (95% CI 0.74 – 0.96) and for calcification was 0.91 (95% 
CI 0.82 – 0.99) (17). The interobserver agreement was good for all measurements. 
The Kappa value for intraplaque hemorrhage was 0.86 (95% CI 0·72 – 0.99); for lipid 
core presence 0.86 (95% CI 0.72 – 0.99) and for calcification 0.94 (95% CI 0.86 – 0.99) 
(17).  
Assessment of antithrombotic treatment  
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Dispensing information for the vitamin K antagonists and antiplatelet agents 
(acetylsalicylic acid [ATC code B01AC06] and carbasalate calcium [ATC code 
B01AC08]) was obtained using a computerized platform linking the study database 
and the pharmacies in the study area. All prescriptions for vitamin K antagonists and 
antiplatelet agents from January 1, 1991, until October 26, 2012, included the 
product name of the drug, the anatomical therapeutic chemical code (ATC code), the 
amount dispensed, the prescribed dose regimen, and the date of dispensing (23, 24). 
The average measured international normalized ratios (INR) (25) were obtained for 
vitamin K antagonists use and daily defined dosage (DDD) was obtained for 
antiplatelet agents use (26). Among the antithrombotic users, we distinguished the 
main therapeutic indications such as atrial fibrillation, recent coronary or 
cerebrovascular events. 
At the time of the MRI, all subjects were classified into one of the following mutually 
exclusive categories: ‘current user’ if the subject was an active user at time of MRI; 
‘past user’ if the subject discontinued the use before the MRI scan date, or ‘never 
user’ if subject never used any of these drugs. We used tertiles for the duration of 
use to classify the use of vitamin K antagonists and antiplatelet agents. This resulted 
in the vitamin K antagonists duration of use ≤ 3 months; duration of use 3 – 11 
months, duration of use > 11 months, and for the antiplatelet agents’ duration of 
use ≤ 30 months; duration of use 30 – 72 months, duration of use > 72 months since 
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the end of the last prescription episode. To facilitate direct dose-dependent relation 
between drugs from the same therapeutic drug group, we used the international 
normalized ratios (25) for the vitamin K antagonists use and a daily dose of 
antiplatelet agents expressed in daily defined dosage (DDD) (26). We created three 
categories of measured INR and DDD and compared them separately with never use. 
The international normalized ratios categories were set based on tertiles and 
antiplatelet daily defined dosage categories were set based on the median. Only five 
subjects, previously treated with vitamin K antagonists due to atrial fibrillation and 
with the recent coronary syndrome, were in concomitant use of dual therapy at the 
time of MRI and none in past use category. Considering the prolonged effect of 
anticoagulation medication, we have not reallocated any subject from past use into 
current use categories among vitamin K antagonists users as a minimum 
discontinuation period was 22 days, but we reclassified 3 subjects in past use 
category, among antiplatelet agent users, to current use category since the minimum 
discontinuation period was 3 – 5 days (25, 27).  
Other risk factors in the Rotterdam Study 
Information on the other cardiovascular risk factors as relevant measurements was 
obtained by interview, physical examination, and blood sampling (15). Among the 
other measures smoking status was categorized into never, the past, and current 
smoking, diabetes mellitus was defined as fasting blood glucose > 6.9 mmol/L, 
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nonfasting glucose > 11.0 mmol/L, or use of glucose-lowering medication, systolic 
and diastolic blood pressure was measured using a random-zero 
sphygmomanometer on the right arm and two measurements were performed and 
the average of the two was used in the analyses. BMI was calculated based on weight 
in kilograms divided by height in meters squared. Serum total cholesterol and HDL 
levels were measured using standard laboratory techniques. We were able to 
consider the use of antihypertensive medication and statin use, which were obtained 
from pharmacy records (15).  
Statistical analysis 
We used the means (standard deviations [SD]), medians (interquartile ranges [IQRs]) 
and percentages to describe the distribution of continuous and categorical variables, 
respectively. To investigate the association between antithrombotic treatment and 
plaque components, intraplaque hemorrhage, lipid core, and calcification, a three-
step statistical analysis approach was used. Initially, we prepared three models, using 
logistic regression, to assess the association of antithrombotic treatment (never, 
current, past) with the presence of each component in one or both carotid arteries. 
In the first model, we adjusted these analyses for age and sex and in second model 
we adjusted for other risk factors. Additionally, in model three for vitamin K 
antagonists users, we adjusted for the international normalized ratios levels. Further, 
as a second step, we examined whether the duration of antithrombotic treatment 
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was associated with any of the plaque components. Third, we assessed whether the 
international normalized ratios levels for vitamin K antagonists and daily defined 
dosages for antiplatelet agents were associated with each plaque component. Finally, 
we performed sensitivity analyses and stratified analyses. First, to address 
confounding by indication, we restricted analyses among subjects without known 
cardiovascular diseases (CVD), only by excluding the participants with known CVD 
history and performed the propensity-score matching for untreated and treated 
participants. Cardiovascular diseases were defined as known and verified the history 
of stroke, myocardial infarction or coronary heart disease. Second, we performed 
stratified analyses for sex and age below and above 70 years of age, to investigate 
whether associations are different between sex and age groups. Antithrombotic 
treatment is usually prescribed to subjects at risk for or with a history of 
cardiovascular diseases.  
All analyses were carried out using IBM SPSS Statistical package version 21 (Chicago, 
IL, USA). 
RESULTS 
The study population characteristics are provided in Table 1. The mean age of the 
population was 72.9 years (SD: 9.1 years) and 46.0% were women. At the time of MRI, 
a total of 6.8% of the participants was using vitamin K antagonists treatment and 
29.9% used antiplatelet (salicylates) treatment. The median vitamin K antagonists use 
CHAPTER 4.2 
175 
 
was 11 months (interquartile range, 3 – 43 months), and median antiplatelet agents 
use was 72 months (interquartile range, 30 – 123 months). The intraplaque 
hemorrhage was more frequently found in the users of antithrombotic treatment 
compared to never-users (Table 2).   
Table 1 Baseline characteristics of the study population (n=1740) 
Age, years (SD) 72.9 ± 9.1 
Women, % 46.0 
Smoking, current % 31.5 
Diabetes mellitus, % 14.4 
Systolic blood pressure, mm/Hg (SD) 145 ± 21 
Diastolic blood pressure, mm/Hg (SD) 80 ± 11 
BMI, kg/m2 (SD) 27.3 ± 3.5 
Total cholesterol, mmol/L (SD) 5.6 ± 1.0 
HDL cholesterol, mmol/L (SD) 1.4 ± 0.3 
Use of antihypertensive medication, % 39.3 
Use of statins, % 29.0 
Vitamin K antagonists         
Current, % 6.8 
Past, % 9.0 
Antiplatelet agents use                      
Current, % 29.9 
Past, % 11.9 
Wall thickness, mm 3.2 ± 0.6 
Degree of stenosis (%)  14.4 (0.0 - 26.8)   
History of stroke, % 6.3 
History of coronary heart disease, % 11.4 
Abbreviations: BMI = body mass index, CHD = coronary heart disease, HDL = High-
density lipoprotein, IPH = intraplaque hemorrhage. Values are means with standard 
deviations or median (interquartile ranges) for continuous variables and percentages 
for dichotomous or categorical variables.  
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Table 2 Presence of the components in the carotid artery plaque according to 
antithrombotic treatment 
 IPH Lipid core Calcification 
Vitamin K antagonists                                                         
Never Use 31.9 43.6 82.0 
Current use 50.4 47.9 87.4 
Past use 48.1 44.9 81.4 
Antiplatelet agents                                         
Never Use 28.6 43.8 78.7 
Current use 42.5 44.4 87.9 
Past use 44.4 44.0 86.0 
           Abbreviations: IPH = intra-plaque hemorrhage. The values represent percentages.  
Antithrombotic therapy and carotid plaque composition 
Table 3 summarizes the associations of oral vitamin K antagonists and antiplatelet 
agents use with the three plaque components. Although not statistically significant, 
we found a trend that current and past use of vitamin K antagonists (adjusted odds 
ratio (OR): 1.88 [95% confidence interval (CI): 0.74-4.75], and OR 1.89 [95%CI: 0.91-
3.93], respectively) (Table 3) and current and past use of antiplatelet agents (OR: 1.22 
[95%CI: 0.91-1.62]), and OR: 1.23 [95%CI: 0.86-1.75], respectively) related to a higher 
presence of intraplaque hemorrhage (Table 3). We found no associations between 
antithrombotic treatment with a lipid core or calcification. 
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Table 3 Association between antithrombotic treatment and carotid artery plaque 
composition 
 
 
IPH 
OR (95%CI) 
Lipid core 
OR (95%CI) 
Calcification 
OR (95%CI) 
Vitamin K Antagonists                                             Model 1 
Never Use Ref Ref Ref 
Current use 1.48 (1.00-2.19) 1.01 (0.69-1.49) 0.96 (0.54-1.71) 
Past use 1.55 (1.10-2.19) 0.97 (0.69-1.36) 0.66 (0.42-1.03) 
Model 2 
Never Use Ref Ref Ref 
Current use 1.34 (0.87-2.06) 1.06 (0.70-1.59) 0.88 (0.48-1.61) 
Past use 1.46 (1.01-2.12) 0.99 (0.70-1.41) 0.59 (0.37-0.94) 
Model 3 
Never Use Ref Ref Ref 
Current use 1.88 (0.74-4.75) 0.87 (0.36-2.11) 1.09 (0.33-3.53) 
Past use 1.89 (0.91-3.93) 0.85 (0.42-1.73) 0.70 (0.28-1.77) 
Antiplatelet agents use                                           Model 1 
Never Use Ref Ref Ref 
Current use 1.46 (1.16-1.84) 0.92 (0.74-1.15) 1.51 (1.10-2.07) 
Past use 1.57 (1.14-2.17) 0.94 (0.69-1.29) 1.19 (0.77-1.84) 
Model 2 
Never Use Ref Ref Ref 
Current use 1.22 (0.91-1.62) 1.00 (0.77-1.30) 1.07 (0.74-1.54) 
Past use 1.23 (0.86-1.75) 0.91 (0.66-1.27) 1.03 (0.65-1.61) 
Abbreviations: CI = confidence interval, INR = international normalized ratio, IPH = intra-
plaque hemorrhage, OR = odds ratios.  
Model 1 – adjusted for age, sex. Model 2 – model 1 + smoking, diabetes mellitus, systolic 
blood pressure, diastolic blood pressure, body mass index, total cholesterol, high-density 
lipoprotein, antihypertensive medication use, statin use and carotid wall thickness.  Model 3 – 
model 2+ average INR. 
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Duration of use and dosage of antithrombotic therapy 
The use of vitamin K antagonists for 3 months or less was not associated with the 
presence of intraplaque hemorrhage whereas the use of vitamin K antagonists for 
more than 3 months was significantly related to the presence of intraplaque 
hemorrhage. This relation became more prominent when we additionally adjusted 
for international normalized ratios levels (adjusted OR: 3.15 [95% CI: 1.23-8.05]) 
(Table 4). The use of antiplatelet agents for less than or more than 30 months was 
not related to the presence of intraplaque hemorrhage (adjusted OR: 1.21 [95% CI: 
0.88 – 1.67]) (Table 4). 
Table 4 Association between duration of use of antithrombotic treatment and IPH in 
the carotid artery 
 IPH 
 
Vitamin K antagonists 
Model 1 
OR (95%CI) 
Model 2 
OR (95%CI) 
Model 3 
OR (95%CI) 
Never Use Ref Ref Ref 
Duration ≤ 3 months 0.81 (0.48-1.37) 0.76 (0.43-1.35) 1.21 (0.51-2.86) 
Duration 3 – 11 months 1.63 (0.99-2.69) 1.62 (0.96-2.76) 2.54 (1.11-5.82) 
Duration > 11 months 1.95 (1.35-2.82) 1.74 (1.16-2.60) 3.15 (1.23-8.05) 
Antiplatelet agents use 
Never Use Ref Ref  
Duration ≤30 months 1.30 (0.92-1.83) 1.14 (0.78-1.66)  
Duration 30–72 months 1.54 (1.10-2.16) 1.32 (0.91-1.92)  
Duration >72 months 1.57 (1.21-2.04) 1.21 (0.88-1.67)  
Abbreviations: CI = confidence interval, INR = international normalized ratio, IPH = intra-
plaque hemorrhage, OR = odds ratios.  
Model 1 – adjusted for age, sex. Model 2 – model 1 + smoking, diabetes mellitus, systolic 
blood pressure, diastolic blood pressure, body mass index, total cholesterol, high-density 
lipoprotein, antihypertensive medication use, statin use and carotid wall thickness.  Model 3 – 
model 2+ average INR. 
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Furthermore, when considering the effect of international normalized ratios and daily 
defined dosages, the dose-response relation was found in both groups. Among oral 
vitamin K antagonist users, international normalized ratios levels higher than 2.97 
were significantly associated with the presence of intraplaque hemorrhage, whereas 
among the antiplatelet users daily defined dosages levels higher than 1.0 were 
significantly associated with the presence of intraplaque hemorrhage (Table 5 and 
Figure 2).  
Table 5 Association of antithrombotic treatment with IPH, according to international 
normalized ratios (INR) for vitamin K antagonists and daily defined dosage (DDD) for 
antiplatelet agents 
 IPH 
Vitamin K antagonists OR (95%CI)  
INR ≤ 2.68  1.56 (0.94-2.56)  
INR 2.69-2.97  1.54 (0.93-2.54)  
INR > 2.97  1.48 (1.03-2.15)  
Antiplatelet agents 
DDD ≤ 0.99  0.71 (0.29-1.76)  
DDD 1.00 – 1.99  1.50 (1.21-1.87)  
DDD > 2.00  2.24 (1.03-4.87)  
Abbreviations: CI = confidence interval, INR = international normalized ratio, IPH = intra-
plaque hemorrhage, OR = odds ratios. The values are adjusted for age and sex. 
 
When restricting our analyses only to subjects without a history of cardiovascular 
diseases, we found a prominent positive trend with intraplaque hemorrhage, among 
current and past users of vitamin K antagonists, and a positive trend with intraplaque 
hemorrhage among current and past users of antiplatelet agents (Supplementary 
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Table 1). Further, propensity-score matched analyses yielded similar results 
(Supplementary Table 2). 
Additionally, investigating for age differences, we found a more prominent 
association of vitamin K antagonists current use with intraplaque hemorrhage in the 
younger age group ≤70 for both drug groups (Supplementary Table 3). Moreover, 
when investigating the sex differences, we found a prominent trend between vitamin 
K antagonists use and intraplaque hemorrhage in females compared to males and 
similar trend between antiplatelet agents use and intraplaque hemorrhage for both 
sexes (Supplementary Table 4). 
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Figure 2 Association of antithrombotic treatment with IPH, according to international 
normalized ratios (INR) for vitamin K antagonists and daily defined dosage (DDD) for 
antiplatelet agents. Values on the y-axis represent the odds ratios and 95% confidence interval. 
The values are adjusted for age and sex. The p-trend in both groups < 0.001. 
DISCUSSION 
In this large population-based sample of individuals with subclinical carotid 
atherosclerosis, we observed that current and past use of antithrombotic treatment 
is associated with intraplaque hemorrhage in the carotid artery plaques. Moreover, 
we found that longer duration of use and higher dosages of antithrombotic 
treatment were related to a higher frequency of intraplaque hemorrhage.  
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The association of antithrombotic treatment with intraplaque hemorrhage in 
atherosclerotic plaques has been studied before, but only in high-risk, symptomatic 
patients. In these studies, it was found that the use of antithrombotic treatment 
related to the presence of intraplaque hemorrhage (8, 28, 29). Moreover, a 
histopathological study on carotid endarterectomy specimens demonstrated an 
effect of antithrombotic treatment on the presence of intraplaque hemorrhage, in 
particular of vitamin K antagonists (28). Apart from this, the earlier study also found 
that before surgical intervention the users of antiplatelet agents, suffered a higher 
presence of multiple hemorrhages in plaques (68% compared to 17%) compared to 
patients who did not use (29). Finally, a recent report from the PARISK-study 
highlighted an association of antiplatelet agents with intraplaque hemorrhage (8). 
Our results further elucidate the effect of antithrombotic treatment on intraplaque 
hemorrhage in carotid atherosclerosis on multiple levels and corroborate findings of 
studies with symptomatic high-risk patients. First, we demonstrated that already in 
the subclinical phase of carotid atherosclerosis there is a prominent association of 
antithrombotic treatment. Second, duration of use is important with regard to the 
presence of intraplaque hemorrhage. Third, independently of other risk factors 
higher levels of international normalized ratios and daily defined dosages influence 
on the presence of intraplaque hemorrhage.   
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One of the main mechanisms underlying the relation of antithrombotic treatment 
with a higher presence of intraplaque hemorrhage may be the leakage of neovessels 
(neovascularization) in the plaque under influence of antithrombotic treatment (8). 
Histological observations suggest that intraplaque hemorrhage arises from the 
adventitia (30), as inward sprouting neovessels towards the plaque and neovessels 
are considered immature and highly susceptible to leakage (31). In this context, we 
hypothesize that antithrombotic treatment may predispose persons to extended 
leakage from neovessels, due to their antithrombotic effects. Additionally, our 
findings may be explained through prior histopathological evidence, which suggests 
that oral vitamin K antagonists relate to hemorrhage from the neovessels within the 
plaque whereas antiplatelet agents increase densities of these neovessels (32, 33). 
Similarly, a capillary bleeding in humans has been found in patients using coumarin-
type anticoagulation (34). On the other hand, animal studies exhibited that capillary 
dilation and permeability, or capillary bleeding, increase when using coumarin-type 
anticoagulants (35-37). Although vitamin K antagonists inhibit the vitamin K 
conversion cycle and salicylates inhibit the platelet aggregation and induce 
vasodilation, both drugs may contribute similarly with their effects in regard to 
intraplaque hemorrhage formation (25, 27).  
These findings seem paradoxical to current knowledge as the goal of antithrombotic 
treatment is to prevent cardiovascular events. Of note is that the beneficial effect of 
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antithrombotic treatment (7) is well documented under medical conditions such as 
ischemic cardiovascular or cerebrovascular diseases (6, 38, 39). Yet, our findings 
emphasize that antithrombotic treatment should be used with care and in low 
dosage (7) and not prescribed unless the clinical benefits outweigh the risks. With 
regard to the clinical effects of antithrombotic treatment, a meta-analysis of two 
large trials (International stroke trial and Chinese acute stroke trial), revealed that 
antithrombotic treatment reduced the risk of ischemic stroke only in the 6-12 weeks 
directly after the stroke, but established no beneficial effect after this period (40). 
Due to the observational nature of the study, the findings should be regarded as 
hypothesis generating and further confirmation is required. 
The major strengths of the current study include the long follow-up time, the 
duration and dosage of exposure to antithrombotic treatment for all study 
participants, as well as the standardized MRI-based assessment of carotid 
atherosclerotic plaques. This is the first population-based study to investigate the 
association of antithrombotic treatment with plaque components in the carotid 
artery within a relatively large study sample. Moreover, the MRI enabled to 
characterize in great detail each specific component of the carotid plaque. 
Nonetheless, some limitations of our study should also be taken into account. First, 
we did not have data on the use of new oral anticoagulants (NOAC’s). Second, as in 
many observational studies investigating the effect of specific medication, we should 
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acknowledge the issue of confounding-by-indication given that antithrombotic 
treatment is more often prescribed to persons with an increased risk of 
cardiovascular diseases. However, sensitivity analysis did not show prominent 
differences in the results. Third, although salicylates are prescribed by doctors, such 
drugs are available ‘over the counter’, and used for other therapeutic indications for 
e.g. like analgesics. Fourth, the cross-sectional design limits our ability to draw causal 
inferences between antithrombotic treatment and intraplaque hemorrhage.  
Conclusion 
The use of antithrombotic treatment relates to a higher frequency of intraplaque 
hemorrhage in carotid atherosclerotic plaques. Further studies are warranted to 
replicate this finding in a longitudinal design. 
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Supplementary Table 1 Association between antithrombotic treatment and IPH in 
individuals free of stroke, myocardial infarction, and coronary heart disease (n= 
1360) 
 IPH 
 
Vitamin K antagonists 
Model 1 
OR (95%CI) 
Model 2 
OR (95%CI) 
Model 3 
OR (95%CI) 
Never Use Ref Ref Ref 
Current use 1.44 (0.86-2.41) 1.40 (0.80-2.43) 3.12 (0.92-10.60) 
Past use 1.34 (0.89-2.00) 1.31 (0.85-2.03) 2.34 (0.95-5.74) 
Antiplatelet agents 
Never Use Ref Ref  
Current use 1.54 (1.15-2.05) 1.15 (0.81-1.61)  
Past use 1.33 (0.90-1.96) 1.16 (0.77-1.77)  
Abbreviations: CI = confidence interval, INR = international normalized ratio, IPH = intra-
plaque hemorrhage, OR = odds ratios. Model 1 - adjusted for age, sex. Model 2 - model 1 + 
smoking, diabetes mellitus, systolic blood pressure, diastolic blood pressure, body mass index, 
total cholesterol, high-density lipoprotein, antihypertensive medication use, statin use and 
carotid wall thickness.  Model 3 – model 2+ average INR. 
 
Supplementary Table 2 Association between antithrombotic treatment and IPH in 
propensity-score matched individuals  
 IPH 
 
Vitamin K antagonists 
Model 1 
OR (95%CI) 
Model 2 
OR (95%CI) 
Model 3 
OR (95%CI) 
Never Use (N=247) Ref Ref Ref 
Vitamin K antagonists use 
(N=247) 
1.39 (0.96 – 2.00) 1.49 (1.00-2.26) 
2.23 (0.97 – 
5.18) 
Antiplatelet agents    
Never Use (N=378) Ref Ref  
Antiplatelet use (N=378) 1.16 (0.86-1.57) 1.16 (0.84-1.60)  
Abbreviations: CI = confidence interval, INR = international normalized ratio, IPH = intra-
plaque hemorrhage, OR = odds ratios. Model 1 - adjusted for age, sex. Model 2 - model 1 + 
smoking, diabetes mellitus, systolic blood pressure, diastolic blood pressure, body mass index, 
total cholesterol, high-density lipoprotein, antihypertensive medication use, statin use and 
carotid wall thickness.  Model 3 – model 2+ average INR. 
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Supplementary Table 3 Association between antithrombotic treatment and IPH in 
the carotid artery, stratified by age 
 IPH 
Age ≤ 70 years 
(n=604) 
Vitamin K 
antagonists 
Model 1 
OR (95%CI) 
Model 2 
OR (95%CI) 
Model 3 
OR (95%CI) 
Never Use Ref Ref Ref 
Current use 6.29 (2.05-19.30) 5.17 (1.55-17.20) 7.72 (0.99-60.35) 
Past use 1.26 (0.54-2.95) 1.10 (0.45-2.67) 1.70 (0.24-12.06) 
Antiplatelet agents 
Never Use Ref Ref  
Current use 1.76 (1.13-2.74) 1.70 (0.97-2.99)  
Past use 2.19 (1.05-4.60) 1.83 (0.83-4.01)  
Age > 70 years 
(n=1136) 
Vitamin K antagonists 
   
Never Use Ref Ref Ref 
Current use 1.39 (0.92-2.09) 1.34 (0.84-2.13) 1.48 (0.50-4.35) 
Past use 1.79 (1.23-2.62) 1.70 (1.12-2.58) 1.84 (0.81-4.15) 
Antiplatelet agents    
Never Use Ref Ref  
Current use 1.51 (1.16-1.98) 1.12 (0.81-1.57)  
Past use 1.62 (1.14-2.31) 1.20 (0.80-1.78)  
Abbreviations: CI = confidence interval, INR = international normalized ratio, IPH = intra-
plaque hemorrhage, OR = odds ratios.  
Model 1 - adjusted for age, sex. Model 2 - model 1 + smoking, diabetes mellitus, systolic blood 
pressure, diastolic blood pressure, body mass index, total cholesterol, high-density lipoprotein, 
antihypertensive medication use, statin use and carotid wall thickness.  Model 3 – model 2+ 
average INR. 
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Supplementary Table 4 Association between antithrombotic treatment and IPH in 
the carotid artery, stratified by sex 
 IPH 
Female (n=800) 
Vitamin K 
antagonists 
Model 1 
OR (95%CI) 
Model 2 
OR (95%CI) 
Model 3 
OR (95%CI) 
Never Use Ref Ref Ref 
Current use 1.36 (0.69-2.65) 1.19 (0.58-2.42) 4.11 (0.86-19.51) 
Past use 1.39 (0.82-2.36) 1.42 (0.81-2.51) 3.44 (1.11-10.63) 
Antiplatelet agents 
Never Use Ref Ref  
Current use 1.46 (1.01-2.12) 1.20 (0.77-1.86)  
Past use 1.35 (0.85-2.17) 1.15 (0.70-1.93)  
Male (n=940) 
Vitamin K 
antagonists 
   
Never Use Ref Ref Ref 
Current use 1.57 (0.96-2.55) 1.43 (0.83-2.46) 1.02 (0.30-3.41) 
Past use 1.67 (1.06-2.64) 1.47 (0.89-2.40) 1.11 (0.41-3.03) 
Antiplatelet agents    
Never Use Ref Ref  
Current use 1.45 (1.08-1.95) 1.21 (0.83-1.75)  
Past use 1.84 (1.17-2.89) 1.32 (0.80-2.18)  
Abbreviations: CI = confidence interval, INR = international normalized ratio, IPH = intra-
plaque hemorrhage, OR = odds ratios.  
Model 1 - adjusted for age, sex. Model 2 - model 1 + smoking, diabetes mellitus, systolic blood 
pressure, diastolic blood pressure, body mass index, total cholesterol, high-density lipoprotein, 
antihypertensive medication use, statin use and carotid wall thickness.  Model 3 – model 2+ 
average INR. 
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Supplementary Table 5 Comparison of the baseline characteristics between 
untreated and treated subjects in unmatched sample  
Vitamin K Antagonists 
Untreated 
(N=1465) 
Treated 
(N=275) 
p-
value 
Standardized 
differences 
Age, years (SD) 72.0 ± 9.2 77.6 ± 7.4 0.00 0.670 
Women, % 47.1 40.0 0.00 –0.143 
Smoking, current % 32.1 28.4 0.05 –0.080 
Diabetes mellitus, % 13.6 18.9 0.00 –0.144 
Systolic blood pressure, 
mm/Hg (SD) 
145 ± 20 147 ± 21 0.04 0.097 
Diastolic blood pressure, 
mm/Hg (SD) 
80 ± 10 79 ± 11 0.06 –0.095 
BMI, kg/m2 (SD) 27.2 ± 3.5 27.9 ± 3.8 0.01 0.191 
Total cholesterol, mmol/L 
(SD) 
5.6 ± 1.0 5.3 ± 1.0 0.00 –0.3 
HDL cholesterol, mmol/L (SD) 1.4 ± 0.3 1.3 ± 0.3 0.02 –0.333 
Use of antihypertensive 
medication, % 
37.2 50.5 0.00 0.270 
Use of statins, % 27.0 39.6 0.00 0.269 
Wall thickness, mm 3.2 ± 0.6 3.4 ± 0.8 0.00 0.281 
Continues variables are reported as means ± standard deviation. Dichotomous 
variables are reported as percentages. 
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Supplementary Table 6 Comparison of the baseline characteristics between 
untreated and treated subjects in matched sample  
Vitamin K Antagonists 
Untreated 
(N=247) 
Treated 
(N=247) 
p-
value 
Standardized 
differences 
Age, years (SD) 75.3 ± 8.0 77.5 ± 7.6 0.00 0.281 
Women, % 44.9 39.3 0.01 –0.113 
Smoking, current % 30.4 30.4 0.56 0 
Diabetes mellitus, % 16.2 20.2 0.02 0.103 
Systolic blood pressure, 
mm/Hg (SD) 
149 ± 21 147 ± 21 0.13 –0.095 
Diastolic blood pressure, 
mm/Hg (SD) 
79 ± 11 79 ± 11 0.72 0 
BMI, kg/m2 (SD) 27.3 ± 3.1 28.0 ± 3.7 0.01 0.205 
Total cholesterol, mmol/L (SD) 5.4 ± 1.0 5.4 ± 1.0 0.55 0 
HDL cholesterol, mmol/L (SD) 1.3 ± 0.3 1.3 ± 0.3 0.44 0 
Use of antihypertensive 
medication, % 
48.6 49.0 0.33 0.008 
Use of statins, % 42.1 36.8 0.02 –0.108 
Wall thickness, mm 3.3 ± 0.8 3.4 ± 0.8 0.24 0.125 
Continues variables are reported as means ± standard deviation. Dichotomous variables are 
reported as percentages. 
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Supplementary Table 7 Comparison of the baseline characteristics between 
untreated and treated subjects in unmatched sample  
Antiplatelet agents 
Untreated 
(N=1013) 
Treated 
(N=727) 
p-
value 
Standardized 
difference 
Age, years (SD) 70.9 ± 9.3 75.6 ± 8.1 0.00 0.538 
Women, % 47.8 43.5 0.00 –0.086 
Smoking, current % 32.4 30.3 0.18 –0.045 
Diabetes mellitus, % 13.2 16.1 0.00 0.082 
Systolic blood pressure, 
mm/Hg (SD) 
143 ± 20 148 ± 20 0.00 0.25 
Diastolic blood pressure, 
mm/Hg (SD) 
81 ± 10 79 ± 11 0.00 –0.190 
BMI, kg/m2 (SD) 27.3 ± 3.6 27.3 ± 3.5 0.86 0 
Total cholesterol, mmol/L (SD) 5.8 ± 0.9 5.3 ± 1.0 0.00 –0.525 
HDL cholesterol, mmol/L (SD) 1.4 ± 0.3 1.3 ± 0.3 0.00 –0.333 
Use of antihypertensive 
medication, % 
30.1 52.1 0.00 0.458 
Use of statins, % 13.3 50.9 0.00 0.879 
Wall thickness, mm 3.1 ± 0.6 3.3 ± 0.7 0.00 0.306 
Continues variables are reported as means ± standard deviation. Dichotomous variables are 
reported as percentages. 
CHAPTER 4.2 
204 
 
Supplementary Table 8 Comparison of the baseline characteristics between 
untreated and treated subjects in matched sample  
Antiplatelet agents 
Untreated 
(N=378) 
Treated 
(N=378) 
p-
value 
Standardized 
difference 
Age, years (SD) 74.9 ± 8.4 74.5 ± 8.4 0.48 –0.047 
Women, % 45.5 48.1 0.17 0.052 
Smoking, current % 30.7 33.1 0.15 0.051 
Diabetes mellitus, % 16.4 16.7 0.84 0.008 
Systolic blood pressure, 
mm/Hg (SD) 
147 ± 19 147 ± 20 0.77 0 
Diastolic blood pressure, 
mm/Hg (SD) 
80 ± 9.9 80 ± 10 0.74 0 
BMI, kg/m2 (SD) 27.3 ± 3.5 27.4 ± 3.6 0.77 0.028 
Total cholesterol, mmol/L (SD) 5.6 ± 0.9 5.6 ± 1.0 0.28 0 
HDL cholesterol, mmol/L (SD) 1.3 ± 0.4 1.3 ± 0.3 0.84 0 
Use of antihypertensive 
medication, % 
42.1 43.1 0.57 0.020 
Use of statins, % 28.6 30.4 0.26 0.039 
Wall thickness, mm 3.2 ± 0.6 3.2 ± 0.7 0.78 0 
Continues variables are reported as means ± standard deviation. Dichotomous variables are 
reported as percentages. 
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In this chapter, the main findings of the thesis are briefly summarized, 
methodological considerations related to the studies are discussed, and the 
clinical implications of the findings along with directions for future research will 
be outlined. 
MAIN FINDINGS 
QUANTIFICATION OF CALCIFICATION USING MRI 
Carotid artery atherosclerosis is an established risk factor for stroke (1, 2). A key 
aim of the prevention of cardiovascular events, including stroke (3), is the early 
identification and treatment of subjects at high risk (4). Calcification is considered 
as a surrogate imaging marker of underlying atherosclerosis (5). Computed 
tomography (CT) and magnetic resonance imaging (MRI) enable detection and 
visualization of the carotid plaque components, although non-contrasted CT is 
superior to any other imaging modality (6) in the detection of calcification, yet, it 
cannot reliably distinguish between intraplaque hemorrhage (IPH) and lipid core 
(7, 8). While non-contrast enhanced MRI is useful to discriminate plaque 
components such as IPH and lipid core,  recent technological developments now 
also allows for detection and quantification of calcification (9). However, whether 
these measurements are as accurate as those obtained with CT remains unclear. 
To address this gap, in chapter 2.1 we compared the absolute volumes of 
calcification, within atherosclerotic plaque in the carotid artery, measured by CT 
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and MRI, among individuals with subclinical atherosclerosis in a population-based 
study (The Rotterdam Study). Our results indicated that MRI-based calcifications 
volumes are comparable and highly correlated (correlation coefficient: 0.86) with 
CT-based volume. Aiming to provide better evidence for the correlation, we 
investigated whether calcification volumes measured with both modalities 
provide similar risk estimates in relation to the history of stroke, in another way 
confirming the correlation of the calcification volumes between MRI and CT.  
Further, considering that our study was performed in subjects with subclinical 
atherosclerosis often asymptomatic and with a low stenosis degree of less than 
28%, MRI was capable to detect the calcification even in small carotid plaques. 
Additional arguments in support to our findings come from the results of a study 
in symptomatic subjects and stenosis degree less or higher than 70% in the 
carotid arteries, suggesting a strong correlation of up to 0.73,  between CT and 
MRI in the measurements of calcifications (10). 
In summary, magnetic resonance imaging (MRI) is a reliable tool for assessing of 
volumetric quantities of carotid plaque components, including calcification and 
soft tissue components, and may be considered a relevant tool for clinical 
examination, research, and clinical decision-making. 
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ROLE OF CIRCULATING HORMONES IN CAROTID ATHEROSCLEROSIS. 
Specific hormonal levels have been associated with the composition of the 
atherosclerotic plaque and its progression hence increasing the risk for 
cardiovascular events (13, 14).  Hormones as risk factors (studied in chapter 3.1 
and 3.2) play an important role in the presence of vulnerable components of 
atherosclerotic plaque. As plaque vulnerability is directly related to the changes 
of a plaque-to-rupture and potential risk of clinical events (15), serum insulin 
levels might provide relevant information for early risk assessment of patients.  
Insulin 
Diabetes mellitus is a well-established risk for cardiovascular diseases, including 
ischemic stroke (16, 17). Dysregulation of the insulin and glucose levels are the 
main features of the diabetes mellitus pathophysiology. Diabetes mellitus is 
associated with an increased risk of cardiovascular diseases due to accelerated 
atherosclerosis (18-21). The leading paradigm on the role of diabetes mellitus 
(22), is attributed to the impaired and high glucose levels (23, 24), namely 
hyperglycemia (25), to be the main cause of vascular complications, which later 
translates consequently to cardiovascular events (26). However, a recent meta-
analysis of 102 prospective studies reported that diabetes mellitus confers excess 
risk for vascular complications and in subjects without diabetes, glucose levels 
were non-linearly associated with risk of vascular diseases, namely the levels 
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below and above of 7.0 mmol/L were associated with increased risk for coronary 
heart disease and ischemic stroke (27), which suggests that the deleterious effect 
of diabetes mellitus is not limited to glucose levels. Our results in this thesis, 
elucidate further the role of insulin in atherosclerotic plaque and provide further 
evidence regarding the pathway linking insulin levels with cardiovascular 
diseases, perhaps through its association with specific characteristics of the 
atherosclerotic plaque.  
Estradiol 
Sex-related differences in risk factor profiles of the atherosclerotic process remain 
understudied. In women, the risk for stroke roughly doubles during the 10-years 
after the menopausal transition (28). These gender differences might be driven 
by endogenous gender hormones and after menopause may influence the plaque 
composition to increase the risk of stroke thereafter. Previously, experimental 
evidence suggested a direct effect of estradiol on the vascular system, affecting 
plaque composition and occurrence of ischemic stroke. In contrast, testosterone 
may slow down atherosclerosis through inhibiting carotid intima-media 
thickening, atheroma formation, hence plaque stability (29). Further, impaired 
levels of estradiol in the postmenopausal woman may explain the gender 
differences in terms of cardiovascular risk. Our study furthermore provides a body 
of evidence by showing an increased risk of stroke in women with established 
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carotid atherosclerosis. This way unraveling a cascade of mechanisms of ischemic 
etiology between the role of hormones on atherosclerotic plaque and stroke.  
ROLE OF CARDIOVASCULAR TREATMENT IN THE COMPOSITION OF THE 
ATHEROSCLEROTIC PLAQUE IN THE CAROTID ARTERY 
Statins 
Statin therapy is a crucial treatment for cardiovascular diseases (30, 31), 
specifically of ischemic origin. In this context, low-density lipoprotein (LDL) 
cholesterol plays a key role (30). Statins proved to be potent drugs capable of 
lowering the concentrations of LDL cholesterol (32) and reducing cardiovascular 
events (33).  The beneficial effect (34) of statins expand beyond lipid-lowering 
effects and might also occur by a direct effect on plaque composition (i.e. 
increasing the calcification and reducing the presence of vulnerable components 
such as lipid core) (35). In contrast to extensive research in coronary arteries (36) 
on the effect of the of statin therapy and mainly on calcification using computed 
tomography, the evidence on the effect of statin on atherosclerosis in the carotid 
arteries and other atherosclerotic plaque components (lipid core and intraplaque 
hemorrhage), is scarce. Moreover, although there was sufficient proof of statins 
to reduce atherosclerosis burden and increase the plaque stability, less is known 
about how statins influence the atherosclerotic plaque composition in the carotid 
arteries. In this chapter, I focused to elaborate further the effect of statins, 
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duration of use and dosage of use. My findings suggest that statins play implies 
changes to a specific composition phenotype of the atherosclerotic plaque. 
Statins were related to the high presence of calcification and lower presence of 
lipid core. Furthermore, our findings on the duration and dosage of the use of 
statins provide novel insights into the time-dependent effects of statins in the 
plaque. Thus, longer duration of use increases the presence of calcification 
whereas only higher dosages of statins are associated with higher levels of 
calcification and lower levels of lipid core. This way I highlight that duration and 
dosage of use could be determining factors of the plaque remodeling process 
and plaque morphology. In addition, in chapter 4.1, we proposed three different 
cutoffs for the duration of use and dosage that may serve as an initial reference 
for different treatment regimes in primary and secondary prevention (37). 
Antithrombotics 
Oral anticoagulants and antiplatelet agents provide a beneficial effect in lowering 
the risk for cardiovascular events, including stroke (38). As such, they play a key 
role in stroke prevention (39, 40). But despite the benefits of oral anticoagulants 
(38), vitamin K antagonists and antiplatelet agents; their effects on the 
development or changes in already existing atherosclerotic plaques were 
unknown. Considering that bleeding is a recognized side effect of antithrombotic 
treatment,  in this chapter, I elaborated the evidence gaps in terms of duration 
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and dosage of use, considering that antithrombotic treatment requires long-term 
use. Previous studies have potentially suggested the link between the use of 
anticoagulant and antiplatelet with the occurrence of intraplaque hemorrhage 
(41, 42). Antithrombotic treatment is the key in the prevention of the 
cardiovascular events and such treatment is prescribed to patients at high-risk of 
due to therapeutic indications such as atrial fibrillation, deep venous thrombosis, 
coronary heart disease, but not due to atherosclerosis. However, given that our 
data provide novel insights on plausible mechanisms on how these drugs 
potentially influence on the levels of vulnerable plaque components such as 
intraplaque hemorrhage, which may lead to plaque instability, their use in primary 
prevention warrants reconsideration and in secondary prevention could require 
careful monitoring of the atherosclerotic plaques. However, the clinical 
significance of these results should be confirmed with the long-term evaluation 
of cardiovascular outcomes (43). 
METHODOLOGICAL CONSIDERATIONS  
The studies described in this thesis were conducted within The Rotterdam Study, 
a prospective population-based cohort study in middle-aged and older adults 
(44). Observational population-based studies provide a unique opportunity to 
study the incidence and etiology of disease, also ability to study disease in 
subclinical phase, and findings may be generalized to a large portion of the 
CHAPTER 5 
214 
 
population (45). The strengths of our studies include a large number of study 
participants, well-characterized components of the atherosclerotic plaque within 
the carotid artery, and extensive information in all study participants on exposure, 
outcome, and potential confounders. Although several advantages, the following 
drawbacks should be considered. Observational studies may be subject to specific 
types of bias, including selection bias. In our studies, we used selection criteria for 
MRI scan of having a thickening of 2.5 mm of the carotid intima-media thickness 
on ultrasound, widely accepted as optimal criteria for the assessment of 
subclinical atherosclerosis in a population-studies (46, 47), for an additional MRI 
scan on selected participants of the Rotterdam Study. When the cutoff 2.5 mm 
was used a selection bias might have been introduced. However, when we 
elaborated the MRI scans the absence of plaque bilaterally was found in several 
participants, that were excluded from the analyses. This information may confirm 
that the use of low cutoff of 2.5 mm along with the standardized protocol with 
ultrasound, during the screening and selection process, and MRI scanning 
protocol has minimized the potential selection bias. Further, potential 
confounders may have had some measurement error or misclassification and 
could have been affected by measurement error. Then, in chapter 4 information 
bias on drug use in context of subjects’ drug adherence to treatment or the use 
of medication such as aspirin for other therapeutic indications e.g. analgesic, 
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might be an issue as potentially introduced unmeasured bias, and due to number 
of subjects with a known history of CVD concerns of confounding by indication 
may be valid. However, to address these types of bias and potential confounding, 
we have performed multiple level testing and extensive sensitivity analyses to 
control for the misleading effects of bias and confounders.  
In this thesis, several studies are characterized by cross-sectional design analyses. 
The known limitation of such analyses is the lack of ability to establish a temporal 
effect, i.e. namely whether determinant precedes the outcome. Specifically, this 
applies to chapters 3.1, 4.1 and 4.2. Nonetheless, using pharmacy records we were 
able to accurately investigate the retrospective duration of use of these 
treatments, chapters 4.1 and 4.2, that might provide to some extent evidence for 
the temporal relationship between exposure and outcome. Yet, here it can be only 
speculated but does not reflect a causal explanation of these processes. However, 
prospective analyses in chapter 3.2 with long term follow-up of participants 
provided evidence for the temporal relation between the exposure and outcome.  
Another important aspect of the methodological consideration is related to MRI 
qualitative and quantitative measurements of the carotid plaque components. 
The validity of the imaging measurements has been addressed with special 
attention through inter-and-intraobserver variability. The results of the inter-and 
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-intraobserver agreement have been extensively described in chapter 2 and 
chapter 4 of this thesis.  
CLINICAL IMPLICATIONS AND FUTURE RESEARCH 
In the final part of this thesis, I focus on the following aspects which may be 
important in future research.  
Magnetic Resonance Imaging (MRI) as a reliable imaging tool for carotid 
plaque assessment 
MRI as an imaging technique to assess the imaging biomarkers of atherosclerosis 
has advantages, including being non-invasive and free of radiation exposure as 
with CT. In chapter 2.1 of this thesis, we used a standardized multisequence MRI 
imaging protocol, which provides important evidence of the capacity of the MRI 
to characterize the atherosclerotic plaque components, including calcification. 
Computed Tomography (CT) is an established imaging tool which is used in 
clinical and research settings but with some important shortcomings. It seems 
that CT is unable to characterize intraplaque hemorrhage (48), a representative 
feature of vulnerable plaques. Also, given the need for radiation exposure, CT 
seems less suitable for prospective serial imaging in asymptomatic patient 
populations. However, MRI does have the potential for serial imaging in the 
asymptomatic patient population for screening strategies without radiation 
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exposure. Furthermore, it may optimize clinical diagnosis and decision-making 
strategies in symptomatic patients with carotid atherosclerosis when it is used in 
clinical settings. Yet, further improvement of reproducible characterization of 
atherosclerotic plaque using MRI imaging is needed, including plaque 
component volumes. Despite the presence or absence of component, the 
volumetric presence of specific component might be the main determinant of the 
plaque rupture or vice-versa. Semi-automated or automated analysis of MRI 
images, including volume quantification, would reduce the extensive laborious 
work of imaging processing and reading and additional would provide 
possibilities to research coexistence of different plaque components and their 
relation with clinical outcomes, such as stroke. In the future involving serial MRI 
studies are probably more promising to understanding subclinical plaque 
transformation into rupture-prone plaque in asymptomatic patients, giving the 
prominent role of MRI use for preventive strategies of ischemic stroke. Further 
efforts should be put in investigating the potential role of carotid plaque 
component on the risk of ischemic stroke, especially their volumetric presence 
within the carotid artery.  
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Hormone levels as risk factors for atherosclerosis 
The studies included in this thesis showed that circulating hormones (insulin and 
sex hormones) are associated with specific aspects of atherosclerosis (Chapters 
3.1 and 3.2), independent of cardiovascular risk factors. The observed association 
between the participants with high levels of insulin were similar to those who 
were free of diabetes mellitus, indicating that serum insulin might be directly 
involved in the atherosclerotic plaque development, already before the DM is 
clinically overt. Although our study is a novel concept in the field, further research 
is warranted to understand the mechanisms of actions and the potential link 
between dysregulated serum insulin levels and atherosclerotic plaque 
development. The previous study addressed the role of the serum insulin on 
cardiovascular diseases and found out that hyperinsulinemia is an independent 
risk factor of ischemic heart disease (13). Whether the role of hyperinsulinemia on 
CVD, is indirectly through worsening of the atherosclerotic plaque, through 
increased presence of vulnerable components e.g. intraplaque hemorrhage and 
lipid core, requires further longitudinal confirmation. Alternatively, longitudinal 
studies with throughout characterization of atherosclerosis burden in subjects 
free of diabetes mellitus may evaluate the direct influence of serum insulin on the 
development of vulnerable components and possibly relate their influence on the 
risk of rupture and consequently to CVD event. 
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On the other hand, results on circulating estradiol suggest that impaired levels, 
after menopause, are implicated with cardiovascular events. This further may 
explain the cardiovascular risk profile difference between men and women in 
middle-age when men are at higher risk for cardiovascular diseases than women. 
After menopause, hormone imbalance is breached, and women are exposed to a 
comparable or even higher risk for cardiovascular events than men. Importantly, 
our results report an association between estradiol and risk of stroke in women 
and regardless of whether an association is causal or not, yet it still can be very 
useful for prediction. Indirectly, observations between estradiol and 
atherosclerotic plaque components may further link the involvement of estradiol 
effect on atherosclerosis in overall and carotid atherosclerotic plaque in particular. 
Although the high levels of estradiol may act as an effect modifier, by influencing 
vulnerable components development indirectly, they may increase the risk of 
stroke directly.  
In the future, from the clinical point of view, incorporating the level of circulating 
hormones in risk estimation scores might provide additional information and 
contribute to better risk assessment for cardiovascular diseases.  
Cardiovascular treatment and the carotid atherosclerotic plaque 
Although atherosclerosis has been considered as a progressive and chronic 
disease, statin treatment has shown to regress atherosclerotic plaque with high-
CHAPTER 5 
220 
 
dose lipid-lowering therapy. In line with previous studies (49, 50) our results add 
to this in showing that statin treatment could transform the composition of the 
atherosclerotic plaque into a more stable phenotype when given in high dosages 
and long duration of use. A molecular mechanism by which statin statins reduce 
the lipid component and enhance plaque calcification, in other words, transform 
plaque into the more stable phenotype, remains to be elucidated. Statins provide 
more observable changes into plaque only when given with high-dose and long-
term use, indicating that both dose and duration of use might determine the 
characteristics and composition of the plaque. In the future, this might be relevant 
clinical information when assigning patient in statin treatment for primary 
prevention of ischemic events due to risk of atherosclerotic thrombo-embolic 
events. Whether the effect of statin on the atherosclerotic plaque is direct, or 
whether it occurs due to their capacity to reduce the systemic lipid levels and/or 
reduce anti-inflammatory processes remains unclear.  
Besides statins, antithrombotic treatment is often used in cardiovascular disease 
prevention. Bleeding is a well-known side effect of antithrombotic treatment, but 
thrombotic occlusion or thrombus embolization plays a major role in the 
pathogenesis of ischemic stroke and myocardial infarction. High-risk patients or 
patients with co-morbidity routinely are treated with antithrombotic treatment to 
prevent cardiovascular events. Moreover, intraplaque hemorrhages within 
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atherosclerotic plaques represent a higher risk for future vascular events and in 
chapter 4.2 we have provided evidence to document the possible effect of 
antithrombotic treatment on the presence of intraplaque hemorrhage. In 
addition, our results add further evidence on how high dosages and longer 
durations influence the presence of intraplaque hemorrhage. In the future, the 
next step is to investigate the potentially harmful effect of antithrombotic 
treatment on atherosclerotic plaque composition and cardiovascular events with 
further confirmation and clinical follow-up.  
CONCLUSION 
MRI is a promising imaging modality for the early detection and serial imaging of 
carotid atherosclerosis with excellent soft-tissue characterization and comparable 
abilities to CT in the detection of calcification. This thesis extends the current 
knowledge on the atherosclerotic plaque in the carotid artery with specific 
aspects of the role of hormones and cardiovascular treatment. Looking at a 
broader perspective, in this thesis we presented novel insights of the association 
of the circulating hormones with specific features of the plaque composition and 
as well as the potential influences of cardiovascular treatment in the progression 
or regression of vulnerable characteristics within the carotid plaque. Moreover, 
future research is needed to replicate our results in other longitudinal designs 
and populations in different geographical regions and to explore underlying 
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mechanisms, and potentially establish of causality between exposure and 
outcome. 
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SUMMARY 
In chapter 1, the general introduction, I provide the general background of carotid 
atherosclerosis, rational and the aim of the thesis. Utilizing the multi-sequenced MRI 
images from the approximately 1,800 participants of the Rotterdam Study, with 
underlying atherosclerotic burden, I examined the roles of hormones and the 
cardiovascular treatment on the carotid plaque composition.  
In chapter 2, I focused on the imaging capability of the MRI, in detection and 
quantification of the calcification, as a reliable biomarker of underlying 
atherosclerotic burden. Chapter 2 reviewed the CT-based and MRI-based detection 
of the calcification, considering the CT as a golden standard for detection and 
quantification of calcification. Although, MRI is powerful in the detection and 
quantification of the soft tissue components, such as lipid core and intraplaque 
hemorrhage, the detection of calcification was seen as the main limitation. 
Quantitative measurements of the calcification have been regarded as optimal 
parameters to compare and validate the MRI-based capacity in the detection and 
quantification of the calcification against the CT-based imaging. Moreover, 
volumetric measurements of calcification obtained by MRI-based scan in relation to 
the history of ischemic stroke as an important clinical outcome provided comparable 
risk estimates as calcification volumetric measurements obtained by CT-based scan, 
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demonstrating that the utilization of MRI for the assessment of vascular calcification 
is similar to that of CT.  
Chapter 3 is devoted to the role of the circulating hormones on the carotid plaque 
composition. In chapter 3.1 I focused on investigating the association of the serum 
insulin levels with atherosclerotic plaque components. Diabetes mellitus is an 
established risk factor for vascular diseases.  Two distinct characteristics of diabetes 
mellitus such as impaired levels of insulin and glucose have been implicated with 
cardiovascular complications. Still, their impact on the atherosclerotic plaque has not 
been previously investigated. Our results, presented in this chapter, associated only 
with impaired serum insulin levels, high and low, with the vulnerable plaque 
components, but not with impaired levels of the serum glucose. These indicate that 
impaired serum insulin levels are implicated with the presence of vulnerable 
components and act as an important part in the pathophysiology of atherosclerotic 
changes within carotid artery. Chapter 3.2 describes the function of sex hormones 
in the composition of the carotid plaque and their potential implications with the risk 
of stroke. Gender differences in risk profiles between men and women for 
cardiovascular diseases might be explained by endogenous hormones. Women after 
the menopause are imposed on higher cardiovascular risk, and sex steroids may take 
on a role to influence on development of more vulnerable carotid plaque and 
thereby increase the stroke incidence when taking into account the levels of total 
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estradiol.  Still, total testosterone was not found to impose a higher risk in either 
gender. 
 Chapter 4 I aimed to investigate the effect of cardiovascular treatment on the 
carotid plaque composition. Statins, in chapter 4.1, through their pleiotropic effect 
proved to influence on the composition of atherosclerotic plaque, by shifting the 
composition towards more stable phenotype, and increasing the presence of 
calcification and reducing the presence of lipid core. Although statins are able to 
change the composition, their duration and dosage of use yielded to be determining 
factor of their effect on the remodeling of atherosclerotic plaque and plaque 
stabilization process. Recounting to the vulnerable plaque concept, plaque 
component such as intraplaque hemorrhage is thought to predispose the plaque to 
rupture. In this context, chapter 4.2, I investigated the association of antithrombotic 
treatment with the presence of intraplaque hemorrhage within the atherosclerotic 
plaque. Antithrombotic treatment may impose a harmful role in the composition of 
carotid plaque by increasing the risk of neovascularization and through extended 
leakage to higher presence of intraplaque hemorrhage, which at a later stage may 
translate to a higher risk for plaque rupture. Yet, antithrombotic treatment is the 
main frontier of cardiovascular events prevention and present findings require 
further confirmation.  
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In chapter 5, the main findings, as well as methodological considerations, are 
discussed along with potential clinical implications and future research. 
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SAMENVATTING 
In hoofdstuk 1, de algemene inleiding, schets ik de algemene achtergrond van 
carotis-atherosclerose en geef ik de rationale en het doel van het proefschrift weer. 
Gebruikmakend van multi-sequence MRI-beelden van de ongeveer 1.800 
deelnemers aan de Rotterdam Study met onderliggende atherosclerotische 
belasting, onderzocht ik het effect van hormonen en de cardiovasculaire medicatie 
op de samenstelling van de carotis-plaque.  
In hoofdstuk 2 richtte ik me op de mogelijkheden van MRI om calcificaties, een 
betrouwbare biomarker van atherosclerotische belasting, te detecteren en 
kwantificeren. CT wordt beschouwd als de gouden standaard hiervoor. Hoewel MRI 
erg geschikt is voor de detectie en kwantificering van zacht weefsel-componenten, 
zoals de lipidenkern of een intra-plaque bloeding, werd de detectie van calcificaties 
gezien als de belangrijkste beperking van MRI. Volumetrische metingen van 
calcificaties op basis van MRI leidden tot vergelijkbare risicoschattingen als CT met 
betrekking tot voorgeschiedenis van ischemische beroerte. Dit toont aan dat MRI 
evenwaardig is aan CT voor de beoordeling van vasculaire calcificaties. 
Hoofdstuk 3 is gewijd aan de rol van de circulerende hormonen in de samenstelling 
van carotis-atherosclerose. In hoofdstuk 3.1 heb ik me gericht op het de associatie 
van serum-insulinespiegels met componenten van atherosclerotische plaque. 
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Diabetes mellitus is een gekende risicofactor voor hart- en vaatziekten. Gestoorde 
insuline- en glucose-spiegels, twee kenmerken van diabetes mellitus, zijn betrokken 
bij cardiovasculaire complicaties. Toch werd hun impact op de atherosclerotische 
plaque niet eerder onderzocht. Op basis van de resultaten gepresenteerd in dit 
hoofdstuk, zijn de kwetsbare plaque-componenten geassocieerd aan gestoorde 
serum-insulinespiegels (zowel te hoge als te lage spiegels), maar niet aan gestoorde 
glucose-spiegels.  Dit geeft aan dat gestoorde serum-insulinespiegels een 
belangrijke rol spelen in de pathofysiologie van atherosclerotische veranderingen 
van de arteria carotis. Hoofdstuk 3.2 beschrijft het effect van geslachtshormonen 
op de samenstelling van de carotis-plaque en hun mogelijke implicaties voor het 
risico op een beroerte. Verschillen tussen mannen en vrouwen in het risico op hart- 
en vaatziekten kunnen worden verklaard door endogene hormonen. 
Postmenopauzale vrouwen hebben een hoger cardiovasculair risico. 
Geslachtssteroïden kunnen een rol spelen bij de ontwikkeling van carotis-
atherosclerose en hierdoor de incidentie van beroerte verhogen rekening houdend 
met de totale estradiolspiegels. Anderzijds bleek totaal testosteron niet gepaard te 
gaan met een hoger risico, in geen van beide geslachten. 
In Hoofdstuk 4 wilde ik het effect onderzoeken van cardiovasculaire medicatie op 
de samenstelling van carotis-atherosclerose. Statines bleken in hoofdstuk 4.1 door 
hun pleiotrope effect de samenstelling van atherosclerotische plaque te beïnvloeden: 
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ze leidden tot een stabieler fenotype door de hoeveelheid calcificatie te vergroten 
en de lipidenkern te verkleinen. De dosis en duur van blootstelling waren bepalende 
factoren in hun effect op de hermodellering van atherosclerotische plaques. Het 
“kwetsbare plaque-concept” stelt dat componenten van de plaque, zoals intra-
plaque bloedingen, de plaque vatbaar maken voor scheuren. In dit verband 
onderzocht ik in hoofdstuk 4.2 de associatie van antitrombotische medicatie met 
intra-plaque bloeding. Antitrombotische medicatie kan een schadelijke invloed 
hebben op de samenstelling van de carotis-plaque, door het risico op 
neovascularisatie te vergroten en door een toename in intra-plaque bloedingen, 
hetgeen zich zou kunnen vertalen in een hoger risico op plaque-scheuren. 
Antitrombotische medicatie is echter een zeer belangrijke tool in de preventie van 
cardiovasculaire events en de huidige bevindingen dienen nog onafhankelijk 
bevestigd te worden. 
In hoofdstuk 5, tenslotte, worden de belangrijkste bevindingen, methodologische 
overwegingen, mogelijke klinische implicaties en toekomstig onderzoek besproken. 
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dua t’i falenderoj ata për edukatën, mësimet dhe gjithçka që kanë bërë për mua dhe 
familjen tonë dhe t’iu përcjellë mesazhin se i dua pa kufishëm dhe se me shumë 
mburrje, krenari e zë të lartë do e them se unë i’u përkasë atyre.  
Që nga koha kur kam filluar këtë rrugëtim familja ime është rritur dhe pasuruar me 
anëtarë të ri por që kurr nuk ka rreshtur të më mbështesë dhe përkrahë. Unë në 
mënyrë të veçant dua t’i falenderoj, për këshillat dhe mbështetjen e vazhdueshme, 
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motrën Violën së bashku me Avniun dhe fëmijët Lianën dhe Dionin, dhe vllaun 
Fatosin së bashku me Adrianën dhe fëmijët Amatin e Duan. Faleminderit të gjithëve.  
Dhe krejt në fund, por jo e fundit për nga rëndësia, dua t’a falenderoj bashkëshorten 
time Leonorën dhe tri princeshat e mija Lea, Lisa edhe Era, për përkrahjen, inspirimin 
e kurajon që më kanë dhënë për të arritur deri në realizimin e këtij qëllimi. Prandaj, 
kjo është një arritje e përbashkët, JU DUA PAFUNDËSISHTË.  
 
Sincerely yours,       3 December 2019 
Blerim Mujaj     Rotterdam, The Netherlands 
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